🏷

Classifications

Harrison's Chapter

Mechanistic Nosology

◆

Subtypes

7

Classical EDS (cEDS) MONDO:0007522

Autosomal dominant inheritance

Characterized by skin hyperextensibility, atrophic scarring, and joint hypermobility.

Show evidence (2 references)

ORPHA:287 SUPPORT Other

"A rare inherited connective tissue disorder characterized by skin hyperextensibility, widened atrophic scars, and generalized joint hypermobility."

Orphanet's definition directly supports the core Classical EDS phenotype triad.

PMID:28192633 SUPPORT

"Classical EDS is a heritable disorder of connective tissue. Patients are affected with joint hypermobility, skin hyperextensibilty, and skin fragility leading to atrophic scarring and significant bruising."

This reference directly supports the claim that Classical EDS (cEDS) is characterized by joint hypermobility, skin hyperextensibility, and atrophic scarring.

Hypermobile EDS (hEDS)

Characterized by generalized joint hypermobility, often with recurrent joint dislocations and chronic pain.

Show evidence (3 references)

PMID:20301456 PARTIAL

"Hypermobile Ehlers-Danlos syndrome (hEDS) is characterized by generalized joint hypermobility, joint instability, pain, soft and hyperextensible skin with atrophic scars and easy bruising..."

While hEDS is characterized by generalized joint hypermobility and chronic pain, the provided literature does not emphasize recurrent joint dislocations as a defining characteristic.

PMID:31582002 PARTIAL

"Symptomatic joint hypermobility can result from soft tissue injury or muscular strain caused by muscular imbalance"

Supports generalized joint hypermobility context, but only partially supports recurrent dislocations/chronic pain framing.

PMID:28145611 SUPPORT

"“The hypermobile type of Ehlers-Danlos syndrome (hEDS) is likely the most common hereditary disorder of connective tissue. It has been described largely in those with musculoskeletal complaints including joint hypermobility, joint subluxations/dislocations, as well as skin and soft tissue..."

This provides direct support for the statement, noting joint hypermobility, recurrent dislocations, and associated chronic pain in hEDS.

Vascular EDS (vEDS)

Most severe form, characterized by thin, translucent skin, arterial, intestinal, and uterine fragility.

Show evidence (4 references)

PMID:33650410 SUPPORT

"The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences."

This excerpt directly supports the statement by confirming that vEDS is characterized by thin, translucent skin, and fragility of arteries, intestines, and uterus.

PMID:32941194 SUPPORT

"Vascular Ehlers-Danlos syndrome (vEDS) is the most severe form of EDS, affecting the synthesis of type III collagen. It is notable for decreased life expectancy and morbidity, including spontaneous vessel rupture."

This excerpt supports the statement by indicating that vEDS is the most severe form of EDS and is associated with significant arterial fragility.

PMID:29709596 SUPPORT

"Life-threatening arterial aneurysms, dissections and ruptures of medium-sized and large arteries are a hallmark of the vascular subtype of EDS, caused by a molecular defect in collagen type III, an important constituent of blood vessel walls and hollow organs."

This excerpt supports the statement by mentioning the severe arterial fragility associated with vEDS.

+ 1 more reference

Kyphoscoliotic EDS (kEDS)

Characterized by kyphoscoliosis, hypotonia, and ocular fragility

Show evidence (2 references)

PMID:18155911 SUPPORT

"The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) (OMIM 225400) is an inherited connective tissue disorder characterized by hypotonia and kyphoscoliosis at birth, joint hypermobility, and skin hyperelasticity and fragility."

The reference describes the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) as having kyphoscoliosis and hypotonia.

PMID:20301635 SUPPORT

"PLOD1-related kyphoscoliotic Ehlers-Danlos syndrome (PLOD1-kEDS) is characterized by hypotonia, generalized joint hypermobility, early-onset kyphoscoliosis, skin fragility, and ocular abnormality."

The reference explicitly lists kyphoscoliosis, hypotonia, and ocular abnormalities as characteristics of PLOD1-kEDS.

Dermatosparaxis EDS

Classical-like EDS

Periodontal EDS

⚙

Pathophysiology

6

Collagen Abnormalities

Mutations in genes encoding collagen or collagen-modifying enzymes lead to defective collagen synthesis and assembly.

collagen fibril organization link collagen biosynthetic process link

Downstream

Connective Tissue Fragility Defective collagen biosynthesis and fibrillogenesis reduce tensile strength of ECM-rich tissues.

Show evidence (5 references)

PMID:7086195 SUPPORT

"Several abnormalities in collagen biosynthesis have been described in patients with Ehlers-Danlos syndrome. Examples of collagen structural mutations as well as post-translational enzymatic defects have been detected."

This reference confirms that mutations affecting collagen synthesis and enzymes responsible for collagen modification are associated with Ehlers-Danlos Syndrome.

PMID:37187299 SUPPORT

"Vascular Ehlers-Danlos Syndrome (vEDS) is a rare autosomal dominant disease caused by mutations in the COL3A1 gene."

This reference identifies specific gene mutations (e.g., COL3A1) responsible for defective collagen synthesis leading to Ehlers-Danlos Syndrome.

PMID:2010058 PARTIAL

"Recently, several mutations in three other collagen genes (COL2A1, COL3A1, and COL4A5) have been found in probands with genetic diseases involving tissues rich in these collagens."

Supports collagen-gene mutation context broadly, but only partially supports this EDS-specific mechanistic descriptor.

+ 2 more references

Connective Tissue Fragility

Abnormal collagen leads to weakened connective tissues throughout the body.

fibroblast link vascular associated smooth muscle cell link

extracellular matrix organization link

dermis link blood vessel link

Downstream

Tissue Injury and Dysfunction Structurally weak connective tissues fail under routine mechanical stress.

Joint Hypermobility Lax ligaments and capsules increase range of motion beyond normal limits.

Skin Hyperextensibility Reduced dermal collagen integrity permits excessive skin stretch.

Arterial Dissection and Rupture Vessel wall fragility increases susceptibility to spontaneous arterial tearing.

Mitral Valve Prolapse Valve connective tissue weakness predisposes to leaflet redundancy and prolapse.

Keratoconus Abnormal stromal collagen architecture contributes to progressive corneal ectasia.

Show evidence (4 references)

PMID:358109 SUPPORT

"The cardinal features are cutaneous hyperextensibility, joint hypermobility, bleeding diathesis, and tissue fragility, and these features lead to a large variety of additional manifestations."

The provided snippet mentions tissue fragility as a cardinal feature of Ehlers-Danlos Syndrome (EDS), which is consistent with the statement that abnormal collagen leads to weakened connective tissues.

PMID:36960056 PARTIAL

"pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex."

Supports periodontal EDS molecular pathology, but only partially supports broad collagen-fragility mechanism across EDS.

PMID:1448 PARTIAL

"Any defect in the normal mechanisms responsible for the synthesis and secretion of collagen molecules or the deposition of these molecules into extracellular fibers could result in abnormal fibrillogenesis; such defects could result in a connective tissue disease."

Provides broad conceptual support for collagen defects and connective tissue disease, but only partially supports this specific descriptor.

+ 1 more reference

Tissue Injury and Dysfunction

Fragile tissues are prone to damage, leading to manifestations like joint dislocations, organ ruptures, and poor wound healing.

Downstream

Poor Wound Healing Collagen defects impair closure strength and scar maturation.

Recurrent Joint Dislocations Chronically unstable joints are prone to repeated subluxation and dislocation.

Chronic Joint Pain Recurrent tissue injury and instability drive persistent musculoskeletal pain.

Gastroesophageal Reflux Visceral connective tissue laxity can compromise gastroesophageal barrier competence.

Decreased Bone Density Altered connective tissue-bone crosstalk contributes to reduced skeletal mineralization.

Hypotonia Soft tissue laxity and impaired force transmission contribute to reduced baseline tone.

Show evidence (3 references)

PMID:24443025 PARTIAL

"The Ehlers-Danlos Syndromes comprise a heterogeneous group of diseases, which are characterized by fragility of the soft connective tissues and widespread manifestations in skin, ligaments and joints, blood vessels and internal organs... The clinical spectrum varies from mild skin and joint..."

The excerpt confirms tissue fragility and various manifestations affecting skin, joints, and internal organs, but does not explicitly mention every detail cited in the statement such as joint dislocations, organ ruptures, or poor wound healing.

PMID:29982180 PARTIAL

"Arterial fragility is an important feature of the disease... Arterial fragility is an important characteristic of kyphoscoliotic EDS. It manifests as spontaneous arterial rupture, dissections and dissecting aneurysms."

The excerpt supports the statement by highlighting arterial fragility and spontaneous ruptures, contributing to tissue injury and dysfunction. However, it does not explicitly mention joint dislocations or poor wound healing.

PMID:19592142 PARTIAL

"Easy bruising and bleeding are prominent features of some heritable disorders of connective tissue (HDCT), resulting from fragility of capillaries and the perivascular connective tissue... In the vascular subtype of EDS, caused by defects in type III collagen, fragility of vessel walls can lead..."

The text discusses tissue fragility leading to bruising and bleeding, supporting aspects of tissue injury and dysfunction. However, it does not explicitly address joint dislocations or organ ruptures.

Integrin-Mediated Mechanotransduction Dysregulation

Defective collagen matrix leads to altered integrin signaling, particularly upregulation of integrin αvβ3, contributing to persistent inflammation and impaired wound healing in classical EDS.

integrin-mediated signaling pathway link inflammatory response link

Downstream

Tissue Injury and Dysfunction Abnormal mechanosignaling reduces tissue resilience during repetitive loading.

Poor Wound Healing Dysregulated integrin signaling impairs coordinated repair responses.

Chronic Joint Pain Persistent inflammatory mechanotransduction amplifies pain signaling in unstable joints.

Autophagy and Proteostasis Dysfunction

Vascular EDS fibroblasts exhibit impaired autophagy-lysosome pathways and cellular stress responses, contributing to abnormal ECM homeostasis and protein quality control.

autophagy link protein folding link

lysosome link autophagosome link

Downstream

Connective Tissue Fragility Impaired proteostasis worsens collagen and matrix protein quality in fibroblasts.

Arterial Dissection and Rupture Chronic cellular stress in vascular connective tissue exacerbates vessel wall vulnerability.

Complement-Mediated ECM Degradation

Intracellular activation of complement C1r/C1s proteases leads to extracellular activated C1s that degrades collagen I, destabilizing the periodontal ECM in periodontal EDS.

complement activation, classical pathway link proteolysis link

periodontium link

Downstream

Connective Tissue Fragility Proteolytic collagen degradation further weakens already abnormal extracellular matrix.

Tissue Injury and Dysfunction Accelerated ECM turnover increases susceptibility to repetitive tissue injury.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

18

Cardiovascular 1

Mitral Valve Prolapse OCCASIONAL Mitral valve prolapse (HP:0001634)

Show evidence (4 references)

PMID:35000503 SUPPORT

"Mitral valve prolapse was present in 7.5% and thoracic aortic dilatation in 15.2%."

This study reports the presence of mitral valve prolapse in patients with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorder (HSD).

PMID:6993166 SUPPORT

"It appears to occur more frequently in females and occasionally it is familial... particularly Marfan's syndrome, rheumatic heart disease, coronary heart disease, congestive cardiomyopathy, ostium secundum atrial septal defect, Ehlers-Danlos syndrome or abnormalities of the thoracic cage."

This reference mentions the association of mitral valve prolapse with Ehlers-Danlos syndrome.

PMID:34776077 SUPPORT

"There is substantial symptoms overlap between the EDS subtypes, and they are associated with an increased incidence of cardiovascular abnormalities, such as mitral valve prolapse and aortic dissection."

This study confirms the association of mitral valve prolapse with Ehlers-Danlos syndrome.

+ 1 more reference

Digestive 1

Gastroesophageal Reflux OCCASIONAL Gastroesophageal reflux (HP:0002020)

Show evidence (3 references)

PMID:26376608 NO_EVIDENCE

"Commonest GI symptoms were: abdominal pain (56.1%), nausea (42.3%), constipation (38.6%), heartburn (37.6%), and irritable bowel syndrome-like symptoms (27.5%)."

The literature mentions heartburn and various other gastrointestinal symptoms but does not specifically mention gastroesophageal reflux as an occasional manifestation.

PMID:36000988 NO_EVIDENCE

"We report a significant enrichment of EDS cases in a set of patients with gastroparesis."

The literature focuses on gastroparesis in EDS patients but does not provide evidence for gastroesophageal reflux as an occasional manifestation.

PMID:34811894 PARTIAL

"Functional aerodigestive manifestations such as inducible laryngeal obstruction may be misdiagnosed as asthma, with gastro-esophageal dysmotility and reflux as common contributing factors."

The literature mentions gastro-esophageal dysmotility and reflux as contributing factors but does not specify the frequency as 'occasional.'

Eye 2

Keratoconus OCCASIONAL Keratoconus (HP:0000563)

Show evidence (5 references)

PMID:36237549 PARTIAL

"In addition to these commonly recognized phenotypes, recent studies have notably highlighted variable ophthalmic features in EDS."

Supports variable ophthalmic involvement generally, but only partially supports keratoconus specifically.

PMID:28757364 NO_EVIDENCE

"As the two patients reported here illustrate, patients with kEDS-PLOD1 do not always have a kyphoscoliosis present at birth or in the first year of life, neither do they necessarily develop kyphoscoliosis later in infancy."

This reference talks mainly about kyphoscoliotic EDS and its genetic underpinnings, without specifically mentioning ophthalmologic features or keratoconus.

PMID:9493273 NO_EVIDENCE

"Keratoconus is most commonly an isolated disorder, although several reports describe an association with Down syndrome, Leber's congenital amaurosis, and mitral valve prolapse."

This reference discusses keratoconus but does not specifically link it to Ehlers-Danlos syndrome.

+ 2 more references

Keratoconus OCCASIONAL Keratoconus (HP:0000563)

Show evidence (2 references)

PMID:36237549 PARTIAL

"In addition to these commonly recognized phenotypes, recent studies have notably highlighted variable ophthalmic features in EDS."

Supports ophthalmic variability generally, but only partially supports keratoconus specifically.

PMID:34501218 PARTIAL

"Because many patients with HDCTs have ocular symptoms, commonly myopia, they will often present to the clinic seeking refractive surgery. Currently, corrective measures are limited, as the FDA contraindicates laser-assisted in-situ keratomileusis (LASIK) in EDS and discourages the procedure in..."

Provides indirect refractive-surgery caution context and only partial support for keratoconus frequency claim.

Integument 5

Skin Hyperextensibility VERY_FREQUENT Hyperextensible skin (HP:0000974)

Show evidence (6 references)

PMID:358109 SUPPORT

"The cardinal features are cutaneous hyperextensibility, joint hypermobility, bleeding diathesis, and tissue fragility..."

The reference clearly states that cutaneous (skin) hyperextensibility is one of the cardinal features of Ehlers-Danlos Syndrome (EDS). This aligns with the statement indicating a high frequency dermatologic phenotype of skin hyperextensibility in EDS.

PMID:30837697 SUPPORT

"All individuals with these atypical variants exhibited skin hyperextensibility as seen in individuals with classical EDS and classical-like EDS..."

The reference shows that skin hyperextensibility is a consistent clinical feature across different EDS subtypes, which supports the statement about its high prevalence as a dermatologic phenotype.

PMID:434850 PARTIAL

"Hyperextensibility of the skin in this region developed within the subsequent five years..."

Case-level localized finding provides only partial support for very-frequent phenotype claim.

+ 3 more references

Poor Wound Healing FREQUENT Poor wound healing (HP:0001058)

Show evidence (4 references)

PMID:19055167 SUPPORT

"Ehlers-Danlos syndrome (EDS) is a heterogeneous group of connective tissue disorders characterized by hyperextensibility, delayed wound healing, joint hypermobility, thin skin, easy bruising, tissue fragility, 'cigarette-paper' scarring over bony prominences, mitral valve prolapse, and other findings."

This reference directly mentions delayed wound healing as a characteristic of Ehlers-Danlos syndrome.

PMID:2728341 PARTIAL

"Although delayed wound healing has been reported to be a complication of Ehlers-Danlos syndrome in humans, using clinical and histologic criteria, wound healing in dogs and cats with Ehlers-Danlos syndrome appears to be similar to nonaffected animals."

Primarily animal data with mixed findings; only partial support for human poor wound-healing frequency.

PMID:20847697 SUPPORT

"Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility."

This reference lists delayed wound healing as a characteristic feature of classic Ehlers-Danlos syndrome.

+ 1 more reference

Atrophic Scars VERY_FREQUENT Atrophic scars (HP:0001075)

Show evidence (1 reference)

ORPHA:287 SUPPORT Other

"HP:0001075 | Atrophic scars | Very frequent (99-80%)"

Orphanet classifies atrophic scars as very frequent in Classical EDS.

Striae Distensae VERY_FREQUENT Striae distensae (HP:0001065)

Show evidence (1 reference)

ORPHA:287 SUPPORT Other

"HP:0001065 | Striae distensae | Very frequent (99-80%)"

Orphanet classifies striae distensae as very frequent in Classical EDS.

Fragile Skin VERY_FREQUENT Fragile skin (HP:0001030)

Show evidence (1 reference)

ORPHA:287 SUPPORT Other

"HP:0001030 | Fragile skin | Very frequent (99-80%)"

Orphanet classifies fragile skin as very frequent in Classical EDS.

Musculoskeletal 4

Joint Hypermobility VERY_FREQUENT Joint hypermobility (HP:0001382)

Sequelae: Recurrent Joint Dislocations Chronic Joint Pain

Show evidence (4 references)

PMID:34807421 SUPPORT

"Currently, musculoskeletal manifestations related to joint hypermobility are perceived as the most prevalent determinants of the quality of life of affected individuals."

This reference confirms that musculoskeletal manifestations, including joint hypermobility, are highly prevalent in individuals with Ehlers-Danlos Syndrome (EDS).

PMID:29915965 PARTIAL

"Increasing data demonstrate that pain is a major disability determinator in JH and EDS. Recent findings confirm a complex pathogenesis for pain in JH and EDS and suggest a potential role for joint instability, central sensitization and small fiber neuropathy."

Supports pain/instability burden in JH/EDS, but only partially supports very-frequent joint hypermobility frequency directly.

PMID:37726791 SUPPORT

"The Ehlers-Danlos syndromes are a group of clinically and genetically heterogeneous hereditary diseases affecting the connective tissue. They are characterized by hypermobility of the joints, hyperextensible skin and friable tissue."

This reference supports the statement by acknowledging hypermobility of the joints as a characteristic of EDS, along with chronic pain and other musculoskeletal features.

+ 1 more reference

Recurrent Joint Dislocations FREQUENT Joint hypermobility (HP:0001382)

Decreased Bone Density VERY_FREQUENT Reduced bone mineral density (HP:0004349)

Systematic review across 839 cases reported decreased bone density prevalence of 90.7%.

Hypotonia FREQUENT Hypotonia (HP:0001252)

Hypotonia and muscular weakness reported in 56.4% of cases across EDS subtypes, particularly prominent in kyphoscoliotic EDS.

Constitutional 1

Chronic Joint Pain FREQUENT Arthralgia (HP:0002829)

Other 4

Cigarette-paper Scars VERY_FREQUENT Cigarette-paper scars (HP:0001073)

Show evidence (1 reference)

ORPHA:287 SUPPORT Other

"HP:0001073 | Cigarette-paper scars | Very frequent (99-80%)"

Orphanet classifies cigarette-paper scars as very frequent in Classical EDS.

Soft, Doughy Skin VERY_FREQUENT Soft, doughy skin (HP:0001027)

Show evidence (1 reference)

ORPHA:287 SUPPORT Other

"HP:0001027 | Soft, doughy skin | Very frequent (99-80%)"

Orphanet classifies soft, doughy skin as very frequent in Classical EDS.

Arterial Dissection and Rupture VERY_FREQUENT

Show evidence (2 references)

PMID:19462862 SUPPORT

"The mutation of the COL3A1 gene which encodes type III collagen, is responsible of early vascular (spontaneous arterial rupture or dissection), digestive (perforation) and obstetrical events (uterine and arterial rupture)"

The literature specifies that the COL3A1 mutation, causing vascular EDS, leads to early vascular events including spontaneous arterial rupture or dissection.

PMID:30999998 PARTIAL

"The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality."

Supports vascular fragility context, but this snippet is treatment-trial focused and only partially supports frequency framing.

Arterial Dissection and Rupture VERY_FREQUENT

Show evidence (5 references)

PMID:19462862 SUPPORT

"The mutation of the COL3A1 gene which encodes type III collagen, is responsible of early vascular (spontaneous arterial rupture or dissection)..."

The abstract explicitly mentions that spontaneous arterial rupture or dissection is a characteristic of vascular Ehlers-Danlos syndrome (vEDS).

PMID:23657781 SUPPORT

"The indication of embolization was spontaneous arterial rupture or pseudoaneurysm with acute bleeding."

The study evaluates the treatment of life-threatening arterial rupture in vEDS patients, indicating that arterial rupture is a significant and frequent concern in this subtype.

PMID:7455751 SUPPORT

"Of the six subtypes of Ehlers-Danlos syndrome, which can usually be clinically differentiated, only types 1 and 4 appear to be associated with a substantial risk of arterial rupture."

This reference highlights that type IV Ehlers-Danlos syndrome (vascular EDS) has a substantial risk of arterial rupture.

+ 2 more references

🧬

Genetic Associations

9

COL1A1 (Pathogenic Variants)

Show evidence (2 references)

PMID:36896471 SUPPORT

"Pathogenic variants in COL1A1 and COL1A2 are involved in osteogenesis imperfecta (OI) and, rarely, Ehlers-Danlos syndrome (EDS) subtypes and OI-EDS overlap syndromes (OIEDS1 and OIEDS2, respectively)."

This statement supports that pathogenic variants in COL1A1 are associated with some subtypes of Ehlers-Danlos Syndrome (EDS).

ORPHA:287 SUPPORT Other

"COL1A1 | collagen type I alpha 1 chain | hgnc:2197 | Disease-causing germline mutation(s) in"

Orphanet lists COL1A1 as a disease-causing germline gene association for Classical EDS.

COL3A1 (Pathogenic Variants)

Show evidence (3 references)

PMID:34560710 SUPPORT

"vEDS patients are at risk of blood vessel rupture due to possession of pathogenic variants of the COL3A1 gene, which encodes type III collagen."

The literature explicitly states that vascular Ehlers-Danlos syndrome (vEDS) is caused by pathogenic variants in the COL3A1 gene.

PMID:30837697 SUPPORT

"Vascular EDS (vEDS) is caused by pathogenic variants in COL3A1, most frequently glycine substitutions."

The abstract confirms the association of vascular EDS with pathogenic variants in the COL3A1 gene.

PMID:35699227 SUPPORT

"Carriers of pathogenic or likely pathogenic COL3A1 variants were retrospectively identified through registries and specialized clinics."

The study supports the association between pathogenic COL3A1 variants and vascular Ehlers-Danlos syndrome.

COL5A1 (Pathogenic Variants)

Show evidence (2 references)

PMID:16278879 SUPPORT

"Mutations in the COL5A1 and the COL5A2 gene, encoding the alpha1 and the alpha2-chain of type V collagen respectively, are identified in approximately 50% of patients with a clinical diagnosis of classic EDS."

The reference clearly states that mutations in the COL5A1 gene are associated with classical Ehlers-Danlos Syndrome, thus supporting the statement.

ORPHA:287 SUPPORT Other

"COL5A1 | collagen type V alpha 1 chain | hgnc:2209 | Disease-causing germline mutation(s) in"

Orphanet lists COL5A1 as a disease-causing germline gene association for Classical EDS.

COL5A2 (Pathogenic Variants)

Show evidence (2 references)

PMID:16278879 SUPPORT

"Mutations in the COL5A1 and the COL5A2 gene, encoding the alpha1 and the alpha2-chain of type V collagen respectively, are identified in approximately 50% of patients with a clinical diagnosis of classic EDS."

The reference confirms that mutations in the COL5A2 gene, encoding the alpha2-chain of type V collagen, are associated with classical EDS and account for approximately 50% of classic EDS cases along with COL5A1.

ORPHA:287 SUPPORT Other

"COL5A2 | collagen type V alpha 2 chain | hgnc:2210 | Disease-causing germline mutation(s) in"

Orphanet lists COL5A2 as a disease-causing germline gene association for Classical EDS.

ADAMTS2 (Pathogenic Variants)

Show evidence (1 reference)

PMID:12646579 SUPPORT

"mutations in the ADAMTS-2 gene in dermatosparaxis and Ehlers-Danlos syndrome VIIC show this enzyme to be responsible in vivo for most biosynthetic processing of procollagen I N-propeptides in skin."

This study demonstrates that ADAMTS2 mutations cause Ehlers-Danlos syndrome type VIIC (dermatosparaxis) by disrupting procollagen processing.

TNXB (Pathogenic Variants)

Show evidence (1 reference)

PMID:36108117 SUPPORT

"The diagnosis of TNXB-related clEDS is established in a proband with suggestive clinical findings and biallelic pathogenic variants in TNXB identified by molecular genetic testing."

This GeneReviews entry confirms that biallelic pathogenic variants in TNXB cause classical-like EDS.

C1R (Pathogenic Variants)

Show evidence (1 reference)

PMID:36960056 SUPPORT

"pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex."

This study demonstrates that C1R mutations cause periodontal EDS by triggering intracellular activation of complement proteases.

C1S (Pathogenic Variants)

Show evidence (1 reference)

PMID:36960056 SUPPORT

"pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex."

This study demonstrates that C1S mutations cause periodontal EDS, with activated C1s degrading collagen I.

PLOD1 (Pathogenic Variants)

Show evidence (4 references)

PMID:32174067 SUPPORT

"Kyphoscoliotic Ehlers-Danlos syndrome (kEDS) is an autosomal recessive connective tissue disorder... The disorder results from a deficiency of the enzyme collagen lysyl hydroxylase 1 due to mutations in the gene PLOD1."

This source clearly states that pathogenic variants in the PLOD1 gene are responsible for kyphoscoliotic Ehlers-Danlos syndrome.

PMID:15979919 SUPPORT

"The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA) is an inheritable connective tissue disorder characterized by a deficiency of lysyl hydroxylase due to mutations in PLOD1."

This reference supports the association between PLOD1 mutations and kyphoscoliotic Ehlers-Danlos syndrome.

PMID:29982180 SUPPORT

"Pathogenic variants in the lysyl-hydroxylase-1 gene (PLOD1) are responsible for the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS)."

This source reinforces the role of PLOD1 pathogenic variants in causing kyphoscoliotic Ehlers-Danlos syndrome.

+ 1 more reference

💊

Treatments

4

Supportive Care

Action: physical therapy MAXO:0000011

Management of pain, physical therapy to strengthen joints, and prevention of complications.

Show evidence (4 references)

PMID:38189943 SUPPORT

"Affected patients require multimodal pain management considering their individual needs, disease-specific features, and comorbidities."

This reference highlights the need for multimodal pain management in Ehlers-Danlos syndrome (EDS) patients, which is a component of supportive care.

PMID:34145717 SUPPORT

"Physiotherapy benefits on proprioception and pain in patients with hEDS even if robust randomized control studies are missing."

This reference supports the use of physical therapy, which strengthens joints and manages pain, aligning with the statement.

PMID:17067502 PARTIAL

"Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active."

Supports multidisciplinary screening/management context, but only partially supports the full supportive-care treatment claim.

+ 1 more reference

Surgical Interventions

Action: surgical procedure MAXO:0000004

May be needed for severe joint instability or life-threatening complications like arterial dissections.

Show evidence (3 references)

PMID:32904109 SUPPORT

"Patients with joint hypermobility syndrome (JHS) might also present with similar symptomatology. This article will focus on the surgical management of patients with knee or shoulder abnormalities related to hEDS/JHS."

This article supports the need for surgical interventions for severe joint instability in patients with hypermobile Ehlers-Danlos Syndrome, which can be considered analogous to severe cases in other types of EDS.

PMID:30999998 NO_EVIDENCE

"The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality... During the period surveyed, the authors observed a statistically significant difference in the ratio of hospitalizations for acute arterial events/hospitalizations for regular follow-up..."

Snippet is pharmacologic trial context and does not directly support surgical intervention.

PMID:33650410 PARTIAL

"The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences."

Supports life-threatening complication profile, but only indirectly supports surgical treatment recommendation.

Lifestyle Modifications

Action: dietary intervention MAXO:0000088

Avoiding high-impact activities and contact sports to prevent injury.

Show evidence (2 references)

PMID:17067502 PARTIAL

"Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active."

Supports screening/management in athletes, but only partially supports explicit avoidance recommendation.

PMID:35756986 PARTIAL

"The results suggest that exercise and rehabilitation may be beneficial for various physical and psychological outcomes."

Supports exercise/rehabilitation benefit generally, but only partial support for avoiding high-impact/contact sports specifically.

Orthotic Interventions

Action: surgical procedure MAXO:0000004

Use of orthotic devices to support unstable joints.

Show evidence (2 references)

PMID:27349123 PARTIAL

"ignorance of effective treatments such as oxygen therapy and orthotics are new concepts that should shake the prejudices derived from the history of this disease."

Provides limited support for orthotics; phrasing is broad and indirect.

PMID:32709178 SUPPORT

"Occupational therapy and bracing were the most effective options with 70% of patients reporting improvement."

This reference supports the use of orthotic devices (e.g., bracing) as effective in the management of EDS.

🌍

Environmental Factors

2

Physical Trauma

Show evidence (3 references)

PMID:26452443 SUPPORT

"Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas."

The snippet indicates that minor physical trauma can exacerbate symptoms by causing severe mucocutaneous injuries in EDS patients.

PMID:28186390 NO_EVIDENCE

"Pain, which is often one of the first symptoms to occur, may be widespread or localized to one region such as an arm or a leg"

Snippet does not directly address physical trauma as an environmental exacerbating factor.

PMID:23095510 PARTIAL

"Optimal therapy for these patients includes the awareness that EDS is a systemic disease involving fragility, bleeding and spontaneous perforations from almost all organ systems."

Supports systemic fragility and complication risk, but only partially supports explicit trauma-exacerbation framing.

Repetitive Motion

Show evidence (2 references)

PMID:31582002 PARTIAL

"Symptomatic joint hypermobility can result from soft tissue injury or muscular strain caused by muscular imbalance."

Supports strain/injury context in hypermobility, but only partially supports repetitive-motion environmental effect claim.

PMID:32175940 PARTIAL

"Thirteen EDS subtypes are recognized, with a wide degree of symptom overlap among subtypes and with other connective tissue disorders."

Although it discusses the overlap of symptoms, it does not directly state that repetitive motion exacerbates these symptoms. However, it implies increased fragility and susceptibility, which could be worsened by repetitive motion.

🔬

Biochemical Markers

1

Collagen Type III (Decreased or Abnormal)

Show evidence (4 references)

PMID:23645670 SUPPORT

"Vascular Ehlers-Danlos syndrome (EDS) type IV is the most severe form of EDS. In many cases the disease is caused by a point mutation of Gly in type III collagen."

This reference indicates that vascular Ehlers-Danlos syndrome (EDS) type IV is caused by mutations in type III collagen, supporting the statement about the abnormal presence of collagen type III in this subtype.

PMID:35245290 SUPPORT

"Vascular Ehlers-Danlos syndrome is a rare inherited disorder caused by genetic variants in type III collagen. Its prognosis is especially hampered by unpredictable arterial ruptures and there is no therapeutic consensus."

This reference clearly indicates that the vascular subtype of Ehlers-Danlos syndrome is caused by variants in type III collagen, supporting the statement.

PMID:34226255 SUPPORT

"Vascular Ehlers-Danlos syndrome is caused by mutations of COL3A1 gene coding for type III collagen. The main clinical features involve a propensity to arterial tears leading to several life-threatening conditions and intensive care unit admission."

This reference again confirms that vascular Ehlers-Danlos syndrome is tied to abnormalities in type III collagen due to mutations in the COL3A1 gene.

+ 1 more reference

{ }

Source YAML

click to show

name: Ehlers-Danlos Syndrome
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-04-28T06:39:31Z'
category: Genetic
parents:
- Connective Tissue Disorder
- Inherited Disorder
external_assertions:
- name: Orphanet Classical Ehlers-Danlos syndrome record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:287
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=287
  description: >-
    Orphanet curates ORPHA:287 as the Classical Ehlers-Danlos syndrome
    disorder record, with exact MONDO and UMLS cross-references and
    narrower ICD-10 and ICD-11 cross-references.
  evidence:
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ORPHA:287  Classical Ehlers-Danlos syndrome"
    explanation: The Orphanet structured record heading identifies ORPHA:287 as the Classical EDS disease record.
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0007522 | Exact"
    explanation: Orphanet maps ORPHA:287 exactly to the MONDO classical EDS subtype identifier.
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-10:Q79.6 | Narrower"
    explanation: Orphanet lists ICD-10 Q79.6 as a broader/narrower cross-reference for the classical EDS record.
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-11:LD28.10 | Narrower"
    explanation: Orphanet lists ICD-11 LD28.10 as a broader/narrower cross-reference for the classical EDS record.
has_subtypes:
- name: Classical EDS
  display_name: Classical EDS (cEDS)
  subtype_term:
    preferred_term: Ehlers-Danlos syndrome, classic type
    term:
      id: MONDO:0007522
      label: Ehlers-Danlos syndrome, classic type
  mappings:
    mondo_mappings:
    - term:
        id: MONDO:0007522
        label: Ehlers-Danlos syndrome, classic type
      mapping_predicate: skos:exactMatch
      mapping_source: ORPHA:287
      mapping_justification: Orphanet lists MONDO:0007522 as an exact cross-reference for Classical EDS.
      consistency:
      - reference: ORPHA:287
        consistent: CONSISTENT
        notes: "MONDO:0007522 | Exact"
  description: Characterized by skin hyperextensibility, atrophic scarring, and joint hypermobility.
  evidence:
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare inherited connective tissue disorder characterized by skin hyperextensibility, widened atrophic scars, and generalized joint hypermobility."
    explanation: Orphanet's definition directly supports the core Classical EDS phenotype triad.
  - reference: PMID:28192633
    reference_title: "Ehlers-Danlos syndrome, classical type."
    supports: SUPPORT
    snippet: Classical EDS is a heritable disorder of connective tissue. Patients are affected with joint hypermobility, skin hyperextensibilty, and skin fragility leading to atrophic scarring and significant bruising.
    explanation: This reference directly supports the claim that Classical EDS (cEDS) is characterized by joint hypermobility, skin hyperextensibility, and atrophic scarring.
  inheritance:
  - name: Autosomal dominant inheritance
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    description: Orphanet classifies Classical EDS as autosomal dominant.
    evidence:
    - reference: ORPHA:287
      reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Autosomal dominant"
      explanation: The Orphanet inheritance section directly states autosomal dominant inheritance for Classical EDS.
- name: Hypermobile EDS
  display_name: Hypermobile EDS (hEDS)
  description: Characterized by generalized joint hypermobility, often with recurrent joint dislocations and chronic pain.
  evidence:
  - reference: PMID:20301456
    reference_title: "Hypermobile Ehlers-Danlos Syndrome."
    supports: PARTIAL
    snippet: Hypermobile Ehlers-Danlos syndrome (hEDS) is characterized by generalized joint hypermobility, joint instability, pain, soft and hyperextensible skin with atrophic scars and easy bruising...
    explanation: While hEDS is characterized by generalized joint hypermobility and chronic pain, the provided literature does not emphasize recurrent joint dislocations as a defining characteristic.
  - reference: PMID:31582002
    reference_title: "Symptomatic Joint Hypermobility: The Hypermobile Type of Ehlers-Danlos Syndrome and the Hypermobility Spectrum Disorders."
    supports: PARTIAL
    snippet: Symptomatic joint hypermobility can result from soft tissue injury or muscular strain caused by muscular imbalance
    explanation: Supports generalized joint hypermobility context, but only partially supports recurrent dislocations/chronic pain framing.
  - reference: PMID:28145611
    reference_title: "Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history."
    supports: SUPPORT
    snippet: “The hypermobile type of Ehlers-Danlos syndrome (hEDS) is likely the most common hereditary disorder of connective tissue. It has been described largely in those with musculoskeletal complaints including joint hypermobility, joint subluxations/dislocations, as well as skin and soft tissue manifestations."
    explanation: This provides direct support for the statement, noting joint hypermobility, recurrent dislocations, and associated chronic pain in hEDS.
- name: Vascular EDS
  display_name: Vascular EDS (vEDS)
  description: Most severe form, characterized by thin, translucent skin, arterial, intestinal, and uterine fragility.
  evidence:
  - reference: PMID:33650410
    reference_title: "Ehlers-Danlos Syndrome Type IV - Anaesthetic Considerations."
    supports: SUPPORT
    snippet: The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences.
    explanation: This excerpt directly supports the statement by confirming that vEDS is characterized by thin, translucent skin, and fragility of arteries, intestines, and uterus.
  - reference: PMID:32941194
    reference_title: "Current management of the vascular subtype of Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos syndrome (vEDS) is the most severe form of EDS, affecting the synthesis of type III collagen. It is notable for decreased life expectancy and morbidity, including spontaneous vessel rupture.
    explanation: This excerpt supports the statement by indicating that vEDS is the most severe form of EDS and is associated with significant arterial fragility.
  - reference: PMID:29709596
    reference_title: "Vascular aspects of the Ehlers-Danlos Syndromes."
    supports: SUPPORT
    snippet: Life-threatening arterial aneurysms, dissections and ruptures of medium-sized and large arteries are a hallmark of the vascular subtype of EDS, caused by a molecular defect in collagen type III, an important constituent of blood vessel walls and hollow organs.
    explanation: This excerpt supports the statement by mentioning the severe arterial fragility associated with vEDS.
  - reference: PMID:30534875
    reference_title: "[Suspected vascular ehlers danlos syndrome. Case report]."
    supports: PARTIAL
    snippet: Ehlers Danlos Syndrome comprises a heterogeneous group of genetic disorders of the connective tissue, due to defects in collagen or its modifying enzymes. We report a 21 years old male presenting with translucent skin revealing the subcutaneous venous pattern.
    explanation: Provides limited case-level support for translucent skin and only partial support for the full severity descriptor.
- description: Characterized by kyphoscoliosis, hypotonia, and ocular fragility
  name: Kyphoscoliotic EDS
  display_name: Kyphoscoliotic EDS (kEDS)
  review_notes: Added an additional clinically relevant subtype.
  evidence:
  - reference: PMID:18155911
    reference_title: "Differential diagnosis of muscular hypotonia in infants: the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI)."
    supports: SUPPORT
    snippet: The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) (OMIM 225400) is an inherited connective tissue disorder characterized by hypotonia and kyphoscoliosis at birth, joint hypermobility, and skin hyperelasticity and fragility.
    explanation: The reference describes the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) as having kyphoscoliosis and hypotonia.
  - reference: PMID:20301635
    reference_title: "PLOD1-Related Kyphoscoliotic Ehlers-Danlos Syndrome."
    supports: SUPPORT
    snippet: PLOD1-related kyphoscoliotic Ehlers-Danlos syndrome (PLOD1-kEDS) is characterized by hypotonia, generalized joint hypermobility, early-onset kyphoscoliosis, skin fragility, and ocular abnormality.
    explanation: The reference explicitly lists kyphoscoliosis, hypotonia, and ocular abnormalities as characteristics of PLOD1-kEDS.
- name: Dermatosparaxis EDS
- name: Classical-like EDS
- name: Periodontal EDS
prevalence:
- population: Global
  percentage: 0.02
  evidence:
  - reference: PMID:28077691
    reference_title: "Establishment and baseline characteristics of a nationwide Danish cohort of patients with Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: The cohort held 1427 unique persons with EDS, giving a national prevalence of 0.02%.
    explanation: The study confirms a prevalence of 0.02%, but this data is specific to the Danish population. The statement claims this prevalence on a global scale, which the provided literature does not support.
- subtype: Classical EDS
  population: Worldwide
  percentage: "1-9 / 100 000"
  notes: Orphanet point-prevalence class for Classical EDS.
  evidence:
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Worldwide | Point prevalence | PMID:20301422,PMID:20847697,EXPERT"
    explanation: Orphanet reports the worldwide point-prevalence class for Classical EDS.
progression:
- phase: Onset
  age_range: Birth-40
  evidence:
  - reference: PMID:32333004
    reference_title: "Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets."
    supports: NO_EVIDENCE
    snippet: Systemic sclerosis is a heterogeneous, multisystem disease. It can occur at any age, but most patients develop the disease between the age of 40 to 50 years.
    explanation: This study is about systemic sclerosis and does not provide evidence regarding the progression or onset of Ehlers-Danlos Syndrome specifically.
  - reference: PMID:21193204
    reference_title: "Cross-sectional and longitudinal assessment of aortic root dilation and valvular anomalies in hypermobile and classic Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: Patients whose first echocardiogram was obtained in late childhood or adulthood were less likely to have aortic dilation (P < .002) than those whose first echocardiogram was obtained in early childhood.
    explanation: Provides partial age-related cardiovascular context but does not directly establish overall onset range.
  - reference: PMID:24499752
    reference_title: "Obstetric and gynecologic challenges in women with Ehlers-Danlos syndrome."
    supports: NO_EVIDENCE
    snippet: There is a much greater prevalence of obstetric and gynecologic issues reported by women with Ehlers-Danlos syndrome than in the general population. Additionally, rates differed significantly among the three most common types of Ehlers-Danlos syndrome with vascular type having the highest rates of adverse pregnancy outcomes and menstrual abnormalities.
    explanation: Snippet addresses obstetric/gynecologic burden and does not directly support onset age range.
  - reference: PMID:29982180
    reference_title: "Arterial fragility in kyphoscoliotic Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: Arterial fragility is an important characteristic of kyphoscoliotic EDS. It manifests as spontaneous arterial rupture, dissections and dissecting aneurysms which may occur even during early childhood.
    explanation: Supports early manifestations in a specific subtype, but only partially supports the broad onset range claim.
- phase: Onset
  subtype: Classical EDS
  age_range: Neonatal to childhood
  notes: Orphanet lists neonatal, infancy, and childhood onset categories for Classical EDS.
  evidence:
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Childhood"
    explanation: Orphanet includes childhood onset for Classical EDS.
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Infancy"
    explanation: Orphanet includes infancy onset for Classical EDS.
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Neonatal"
    explanation: Orphanet includes neonatal onset for Classical EDS.
- age_range: 10-30
  phase: Peak Symptoms Development
  review_notes: Added an additional phase to describe the common age range where symptoms peak.
  evidence:
  - reference: PMID:37261967
    reference_title: "Clinical trajectory of hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders in older adults."
    supports: REFUTE
    snippet: 'OBJECTIVE: This review sought to identify studies regarding aging in hEDS/HSD... No study had a stated aim regarding aging in hEDS/HSD, but all studies corroborated earlier natural history studies describing the age-related trajectory of manifestations in younger people. Studies found that symptom progression was heterogeneous, multisystemic, and unpredictable.'
    explanation: The statement that there is a common age range where symptoms peak is refuted by the literature's indication that symptom progression is heterogeneous, multisystemic, and unpredictable.
pathophysiology:
- name: Collagen Abnormalities
  description: Mutations in genes encoding collagen or collagen-modifying enzymes lead to defective collagen synthesis and assembly.
  biological_processes:
  - preferred_term: collagen fibril organization
    term:
      id: GO:0030199
      label: collagen fibril organization
  - preferred_term: collagen biosynthetic process
    term:
      id: GO:0032964
      label: collagen biosynthetic process
  evidence:
  - reference: PMID:7086195
    reference_title: "Molecular defects in the Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: Several abnormalities in collagen biosynthesis have been described in patients with Ehlers-Danlos syndrome. Examples of collagen structural mutations as well as post-translational enzymatic defects have been detected.
    explanation: This reference confirms that mutations affecting collagen synthesis and enzymes responsible for collagen modification are associated with Ehlers-Danlos Syndrome.
  - reference: PMID:37187299
    reference_title: "Patient-derived extracellular matrix demonstrates role of COL3A1 in blood vessel mechanics."
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos Syndrome (vEDS) is a rare autosomal dominant disease caused by mutations in the COL3A1 gene.
    explanation: This reference identifies specific gene mutations (e.g., COL3A1) responsible for defective collagen synthesis leading to Ehlers-Danlos Syndrome.
  - reference: PMID:2010058
    reference_title: "Mutations in collagen genes: causes of rare and some common diseases in humans."
    supports: PARTIAL
    snippet: Recently, several mutations in three other collagen genes (COL2A1, COL3A1, and COL4A5) have been found in probands with genetic diseases involving tissues rich in these collagens.
    explanation: Supports collagen-gene mutation context broadly, but only partially supports this EDS-specific mechanistic descriptor.
  - reference: PMID:30246406
    reference_title: "A frameshift variant in the COL5A1 gene in a cat with Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: Human EDS may be caused by variants in several different genes including COL5A1, which encodes the collagen type V alpha 1 chain.
    explanation: Supports COL5A1 relevance via non-human model context, providing partial support.
  - reference: PMID:30668708
    reference_title: "Bi-allelic AEBP1 mutations in two patients with Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: Bi-allelic loss-of-function mutations in the adipocyte enhancer-binding protein 1 (AEBP1) gene were reported in three families with an autosomal recessive EDS-like condition.
    explanation: Supports an EDS-like condition and provides only partial support for generalized collagen-abnormality claim in EDS.
  downstream:
  - target: Connective Tissue Fragility
    description: Defective collagen biosynthesis and fibrillogenesis reduce tensile strength of ECM-rich tissues.
- name: Connective Tissue Fragility
  description: Abnormal collagen leads to weakened connective tissues throughout the body.
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: vascular associated smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  locations:
  - preferred_term: dermis
    term:
      id: UBERON:0002067
      label: dermis
  - preferred_term: blood vessel
    term:
      id: UBERON:0001981
      label: blood vessel
  evidence:
  - reference: PMID:358109
    reference_title: "Heritable disorders of connective tissue: Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: The cardinal features are cutaneous hyperextensibility, joint hypermobility, bleeding diathesis, and tissue fragility, and these features lead to a large variety of additional manifestations.
    explanation: The provided snippet mentions tissue fragility as a cardinal feature of Ehlers-Danlos Syndrome (EDS), which is consistent with the statement that abnormal collagen leads to weakened connective tissues.
  - reference: PMID:36960056
    reference_title: "Degradation of collagen I by activated C1s in periodontal Ehlers-Danlos Syndrome."
    supports: PARTIAL
    snippet: pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex.
    explanation: Supports periodontal EDS molecular pathology, but only partially supports broad collagen-fragility mechanism across EDS.
  - reference: PMID:1448
    reference_title: "Defects in the biochemistry of collagen in diseases of connective tissue."
    supports: PARTIAL
    snippet: Any defect in the normal mechanisms responsible for the synthesis and secretion of collagen molecules or the deposition of these molecules into extracellular fibers could result in abnormal fibrillogenesis; such defects could result in a connective tissue disease.
    explanation: Provides broad conceptual support for collagen defects and connective tissue disease, but only partially supports this specific descriptor.
  - reference: PMID:31329366
    reference_title: "An update on the new classification of Ehlers-Danlos syndrome and review of the causes of bleeding in this population."
    supports: SUPPORT
    snippet: Collagen, which forms the framework of vessel walls, is altered in many patients with Ehlers-Danlos syndrome (EDS) leading to weakening of the vessel wall or the supporting tissues.
    explanation: This reference directly supports the statement by mentioning how altered collagen in EDS patients leads to weakening of vessel walls and supporting tissues.
  downstream:
  - target: Tissue Injury and Dysfunction
    description: Structurally weak connective tissues fail under routine mechanical stress.
  - target: Joint Hypermobility
    description: Lax ligaments and capsules increase range of motion beyond normal limits.
  - target: Skin Hyperextensibility
    description: Reduced dermal collagen integrity permits excessive skin stretch.
  - target: Arterial Dissection and Rupture
    description: Vessel wall fragility increases susceptibility to spontaneous arterial tearing.
  - target: Mitral Valve Prolapse
    description: Valve connective tissue weakness predisposes to leaflet redundancy and prolapse.
  - target: Keratoconus
    description: Abnormal stromal collagen architecture contributes to progressive corneal ectasia.
- name: Tissue Injury and Dysfunction
  description: Fragile tissues are prone to damage, leading to manifestations like joint dislocations, organ ruptures, and poor wound healing.
  evidence:
  - reference: PMID:24443025
    reference_title: "The Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: The Ehlers-Danlos Syndromes comprise a heterogeneous group of diseases, which are characterized by fragility of the soft connective tissues and widespread manifestations in skin, ligaments and joints, blood vessels and internal organs... The clinical spectrum varies from mild skin and joint hyperlaxity to severe physical disability and life-threatening vascular complications.
    explanation: The excerpt confirms tissue fragility and various manifestations affecting skin, joints, and internal organs, but does not explicitly mention every detail cited in the statement such as joint dislocations, organ ruptures, or poor wound healing.
  - reference: PMID:29982180
    reference_title: "Arterial fragility in kyphoscoliotic Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: Arterial fragility is an important feature of the disease... Arterial fragility is an important characteristic of kyphoscoliotic EDS. It manifests as spontaneous arterial rupture, dissections and dissecting aneurysms.
    explanation: The excerpt supports the statement by highlighting arterial fragility and spontaneous ruptures, contributing to tissue injury and dysfunction. However, it does not explicitly mention joint dislocations or poor wound healing.
  - reference: PMID:19592142
    reference_title: "Bleeding in the heritable connective tissue disorders: mechanisms, diagnosis and treatment."
    supports: PARTIAL
    snippet: Easy bruising and bleeding are prominent features of some heritable disorders of connective tissue (HDCT), resulting from fragility of capillaries and the perivascular connective tissue... In the vascular subtype of EDS, caused by defects in type III collagen, fragility of vessel walls can lead to life-threatening bleeding and premature death.
    explanation: The text discusses tissue fragility leading to bruising and bleeding, supporting aspects of tissue injury and dysfunction. However, it does not explicitly address joint dislocations or organ ruptures.
  downstream:
  - target: Poor Wound Healing
    description: Collagen defects impair closure strength and scar maturation.
  - target: Recurrent Joint Dislocations
    description: Chronically unstable joints are prone to repeated subluxation and dislocation.
  - target: Chronic Joint Pain
    description: Recurrent tissue injury and instability drive persistent musculoskeletal pain.
  - target: Gastroesophageal Reflux
    description: Visceral connective tissue laxity can compromise gastroesophageal barrier competence.
  - target: Decreased Bone Density
    description: Altered connective tissue-bone crosstalk contributes to reduced skeletal mineralization.
  - target: Hypotonia
    description: Soft tissue laxity and impaired force transmission contribute to reduced baseline tone.
- name: Integrin-Mediated Mechanotransduction Dysregulation
  description: Defective collagen matrix leads to altered integrin signaling, particularly upregulation of integrin αvβ3, contributing to persistent inflammation and impaired wound healing in classical EDS.
  subtypes:
  - Classical EDS
  biological_processes:
  - preferred_term: integrin-mediated signaling pathway
    term:
      id: GO:0007229
      label: integrin-mediated signaling pathway
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  notes: Research demonstrates that COL5A1-deficient wounds show increased αvβ3 integrin and IL-1β with reduced mechanical strength; integrin antagonism partially rescues wound healing.
  downstream:
  - target: Tissue Injury and Dysfunction
    description: Abnormal mechanosignaling reduces tissue resilience during repetitive loading.
  - target: Poor Wound Healing
    description: Dysregulated integrin signaling impairs coordinated repair responses.
  - target: Chronic Joint Pain
    description: Persistent inflammatory mechanotransduction amplifies pain signaling in unstable joints.
- name: Autophagy and Proteostasis Dysfunction
  description: Vascular EDS fibroblasts exhibit impaired autophagy-lysosome pathways and cellular stress responses, contributing to abnormal ECM homeostasis and protein quality control.
  subtypes:
  - Vascular EDS
  biological_processes:
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
  - preferred_term: protein folding
    term:
      id: GO:0006457
      label: protein folding
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  - preferred_term: autophagosome
    term:
      id: GO:0005776
      label: autophagosome
  notes: Multi-omics analysis of vEDS patient fibroblasts revealed dysregulated autophagy-lysosome pathways and miRNA regulation (miR-29b-3p).
  downstream:
  - target: Connective Tissue Fragility
    description: Impaired proteostasis worsens collagen and matrix protein quality in fibroblasts.
  - target: Arterial Dissection and Rupture
    description: Chronic cellular stress in vascular connective tissue exacerbates vessel wall vulnerability.
- name: Complement-Mediated ECM Degradation
  description: Intracellular activation of complement C1r/C1s proteases leads to extracellular activated C1s that degrades collagen I, destabilizing the periodontal ECM in periodontal EDS.
  subtypes:
  - Periodontal EDS
  biological_processes:
  - preferred_term: complement activation, classical pathway
    term:
      id: GO:0006958
      label: complement activation, classical pathway
  - preferred_term: proteolysis
    term:
      id: GO:0006508
      label: proteolysis
  locations:
  - preferred_term: periodontium
    term:
      id: UBERON:0001758
      label: periodontium
  notes: Research demonstrates activated C1s degrades collagen I in patient fibroblasts, causing high collagen turnover and periodontal tissue destruction.
  downstream:
  - target: Connective Tissue Fragility
    description: Proteolytic collagen degradation further weakens already abnormal extracellular matrix.
  - target: Tissue Injury and Dysfunction
    description: Accelerated ECM turnover increases susceptibility to repetitive tissue injury.
phenotypes:
- category: Musculoskeletal
  name: Joint Hypermobility
  frequency: VERY_FREQUENT
  diagnostic: true
  sequelae:
  - target: Recurrent Joint Dislocations
  - target: Chronic Joint Pain
  evidence:
  - reference: PMID:34807421
    reference_title: "Ehlers-Danlos Syndromes, Joint Hypermobility and Hypermobility Spectrum Disorders."
    supports: SUPPORT
    snippet: Currently, musculoskeletal manifestations related to joint hypermobility are perceived as the most prevalent determinants of the quality of life of affected individuals.
    explanation: This reference confirms that musculoskeletal manifestations, including joint hypermobility, are highly prevalent in individuals with Ehlers-Danlos Syndrome (EDS).
  - reference: PMID:29915965
    reference_title: "Clinical Relevance of Joint Hypermobility and Its Impact on Musculoskeletal Pain and Bone Mass."
    supports: PARTIAL
    snippet: Increasing data demonstrate that pain is a major disability determinator in JH and EDS. Recent findings confirm a complex pathogenesis for pain in JH and EDS and suggest a potential role for joint instability, central sensitization and small fiber neuropathy.
    explanation: Supports pain/instability burden in JH/EDS, but only partially supports very-frequent joint hypermobility frequency directly.
  - reference: PMID:37726791
    reference_title: "Prevalence and quality of temporomandibular disorders, chronic pain and psychological distress in patients with classical and hypermobile Ehlers-Danlos syndrome: an exploratory study."
    supports: SUPPORT
    snippet: The Ehlers-Danlos syndromes are a group of clinically and genetically heterogeneous hereditary diseases affecting the connective tissue. They are characterized by hypermobility of the joints, hyperextensible skin and friable tissue.
    explanation: This reference supports the statement by acknowledging hypermobility of the joints as a characteristic of EDS, along with chronic pain and other musculoskeletal features.
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002761 | Generalized joint laxity | Very frequent (99-80%)"
    explanation: Orphanet classifies generalized joint hypermobility/laxity as very frequent in Classical EDS.
  phenotype_term:
    preferred_term: Joint Hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
- category: Dermatologic
  name: Skin Hyperextensibility
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:358109
    reference_title: "Heritable disorders of connective tissue: Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: The cardinal features are cutaneous hyperextensibility, joint hypermobility, bleeding diathesis, and tissue fragility...
    explanation: The reference clearly states that cutaneous (skin) hyperextensibility is one of the cardinal features of Ehlers-Danlos Syndrome (EDS). This aligns with the statement indicating a high frequency dermatologic phenotype of skin hyperextensibility in EDS.
  - reference: PMID:30837697
    reference_title: "Atypical COL3A1 variants (glutamic acid to lysine) cause vascular Ehlers-Danlos syndrome with a consistent phenotype of tissue fragility and skin hyperextensibility."
    supports: SUPPORT
    snippet: All individuals with these atypical variants exhibited skin hyperextensibility as seen in individuals with classical EDS and classical-like EDS...
    explanation: The reference shows that skin hyperextensibility is a consistent clinical feature across different EDS subtypes, which supports the statement about its high prevalence as a dermatologic phenotype.
  - reference: PMID:434850
    reference_title: "Localized Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: Hyperextensibility of the skin in this region developed within the subsequent five years...
    explanation: Case-level localized finding provides only partial support for very-frequent phenotype claim.
  - reference: PMID:31904772
    reference_title: "The Many Facets of Hypermobile Ehlers-Danlos Syndrome."
    supports: PARTIAL
    snippet: Of the 13 subtypes of Ehlers-Danlos Syndromes (EDSs)...the authors provide an overview of hEDS symptoms and... current treatment options.
    explanation: Broad overview context provides only partial direct support for this specific phenotype-frequency claim.
  - reference: PMID:6733946
    reference_title: "Dermal changes in Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: Collagen fibrils showed a distorted arrangement... abnormal collagen fibrils in normal skin suggests one of eight types of Ehlers-Danlos syndrome.
    explanation: Supports dermal collagen abnormality, but only partially supports skin hyperextensibility frequency directly.
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000974 | Hyperextensible skin | Very frequent (99-80%)"
    explanation: Orphanet classifies hyperextensible skin as very frequent in Classical EDS.
  phenotype_term:
    preferred_term: Hyperextensible skin
    term:
      id: HP:0000974
      label: Hyperextensible skin
- category: Dermatologic
  name: Poor Wound Healing
  frequency: FREQUENT
  evidence:
  - reference: PMID:19055167
    reference_title: "A \"hyperextensive\" review of Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: Ehlers-Danlos syndrome (EDS) is a heterogeneous group of connective tissue disorders characterized by hyperextensibility, delayed wound healing, joint hypermobility, thin skin, easy bruising, tissue fragility, 'cigarette-paper' scarring over bony prominences, mitral valve prolapse, and other findings.
    explanation: This reference directly mentions delayed wound healing as a characteristic of Ehlers-Danlos syndrome.
  - reference: PMID:2728341
    reference_title: "Cutaneous wound healing in Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: Although delayed wound healing has been reported to be a complication of Ehlers-Danlos syndrome in humans, using clinical and histologic criteria, wound healing in dogs and cats with Ehlers-Danlos syndrome appears to be similar to nonaffected animals.
    explanation: Primarily animal data with mixed findings; only partial support for human poor wound-healing frequency.
  - reference: PMID:20847697
    reference_title: "Clinical and genetic aspects of Ehlers-Danlos syndrome, classic type."
    supports: SUPPORT
    snippet: Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility.
    explanation: This reference lists delayed wound healing as a characteristic feature of classic Ehlers-Danlos syndrome.
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001058 | Poor wound healing | Frequent (79-30%)"
    explanation: Orphanet classifies poor wound healing as frequent in Classical EDS.
  phenotype_term:
    preferred_term: Poor Wound Healing
    term:
      id: HP:0001058
      label: Poor wound healing
- category: Dermatologic
  name: Atrophic Scars
  frequency: VERY_FREQUENT
  subtype: Classical EDS
  diagnostic: true
  evidence:
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001075 | Atrophic scars | Very frequent (99-80%)"
    explanation: Orphanet classifies atrophic scars as very frequent in Classical EDS.
  phenotype_term:
    preferred_term: Atrophic scars
    term:
      id: HP:0001075
      label: Atrophic scars
- category: Dermatologic
  name: Cigarette-paper Scars
  frequency: VERY_FREQUENT
  subtype: Classical EDS
  evidence:
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001073 | Cigarette-paper scars | Very frequent (99-80%)"
    explanation: Orphanet classifies cigarette-paper scars as very frequent in Classical EDS.
  phenotype_term:
    preferred_term: Cigarette-paper scars
    term:
      id: HP:0001073
      label: Cigarette-paper scars
- category: Dermatologic
  name: Striae Distensae
  frequency: VERY_FREQUENT
  subtype: Classical EDS
  evidence:
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001065 | Striae distensae | Very frequent (99-80%)"
    explanation: Orphanet classifies striae distensae as very frequent in Classical EDS.
  phenotype_term:
    preferred_term: Striae distensae
    term:
      id: HP:0001065
      label: Striae distensae
- category: Dermatologic
  name: Soft, Doughy Skin
  frequency: VERY_FREQUENT
  subtype: Classical EDS
  evidence:
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001027 | Soft, doughy skin | Very frequent (99-80%)"
    explanation: Orphanet classifies soft, doughy skin as very frequent in Classical EDS.
  phenotype_term:
    preferred_term: Soft, doughy skin
    term:
      id: HP:0001027
      label: Soft, doughy skin
- category: Dermatologic
  name: Fragile Skin
  frequency: VERY_FREQUENT
  subtype: Classical EDS
  evidence:
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001030 | Fragile skin | Very frequent (99-80%)"
    explanation: Orphanet classifies fragile skin as very frequent in Classical EDS.
  phenotype_term:
    preferred_term: Fragile skin
    term:
      id: HP:0001030
      label: Fragile skin
- category: Cardiovascular
  name: Arterial Dissection and Rupture
  frequency: VERY_FREQUENT
  subtype: Vascular EDS
  evidence:
  - reference: PMID:19462862
    reference_title: "[Vascular Ehlers-Danlos syndrome]."
    supports: SUPPORT
    snippet: The mutation of the COL3A1 gene which encodes type III collagen, is responsible of early vascular (spontaneous arterial rupture or dissection), digestive (perforation) and obstetrical events (uterine and arterial rupture)
    explanation: The literature specifies that the COL3A1 mutation, causing vascular EDS, leads to early vascular events including spontaneous arterial rupture or dissection.
  - reference: PMID:30999998
    reference_title: "Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study."
    supports: PARTIAL
    snippet: The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality.
    explanation: Supports vascular fragility context, but this snippet is treatment-trial focused and only partially supports frequency framing.
- category: Ophthalmologic
  frequency: OCCASIONAL
  name: Keratoconus
  review_notes: Added less common phenotype for better completeness.
  evidence:
  - reference: PMID:36237549
    reference_title: "Ehlers-Danlos syndromes and their manifestations in the visual system."
    supports: PARTIAL
    snippet: In addition to these commonly recognized phenotypes, recent studies have notably highlighted variable ophthalmic features in EDS.
    explanation: Supports variable ophthalmic involvement generally, but only partially supports keratoconus specifically.
  - reference: PMID:28757364
    reference_title: "Ehlers Danlos syndrome, kyphoscoliotic type due to Lysyl Hydroxylase 1 deficiency in two children without congenital or early onset kyphoscoliosis."
    supports: NO_EVIDENCE
    snippet: As the two patients reported here illustrate, patients with kEDS-PLOD1 do not always have a kyphoscoliosis present at birth or in the first year of life, neither do they necessarily develop kyphoscoliosis later in infancy.
    explanation: This reference talks mainly about kyphoscoliotic EDS and its genetic underpinnings, without specifically mentioning ophthalmologic features or keratoconus.
  - reference: PMID:9493273
    reference_title: "Keratoconus."
    supports: NO_EVIDENCE
    snippet: Keratoconus is most commonly an isolated disorder, although several reports describe an association with Down syndrome, Leber's congenital amaurosis, and mitral valve prolapse.
    explanation: This reference discusses keratoconus but does not specifically link it to Ehlers-Danlos syndrome.
  - reference: PMID:14679583
    reference_title: "Brittle cornea syndrome and its delineation from the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI): report on 23 patients and review of the literature."
    supports: NO_EVIDENCE
    snippet: The brittle cornea syndrome (BCS) is a generalized connective tissue disorder characterized by corneal rupture following only minor trauma, keratoconus or keratoglobus, blue sclerae, hyperelasticity of the skin without excessive fragility, and hypermobility of the joints.
    explanation: Snippet is about brittle cornea syndrome and does not directly provide EDS keratoconus evidence.
  - reference: PMID:37074408
    reference_title: "Keratoconus tomographic indices in osteogenesis imperfecta."
    supports: NO_EVIDENCE
    snippet: A high proportion of patients had tomographically suspect corneas when using keratoconus diagnostic indices
    explanation: This reference discusses keratoconus in the context of osteogenesis imperfecta, not Ehlers-Danlos syndrome.
  phenotype_term:
    preferred_term: Keratoconus
    term:
      id: HP:0000563
      label: Keratoconus
- category: Cardiovascular
  frequency: OCCASIONAL
  name: Mitral Valve Prolapse
  review_notes: Added this cardiovascular manifestation seen in some EDS subtypes.
  evidence:
  - reference: PMID:35000503
    reference_title: "Cardiovascular manifestations of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders."
    supports: SUPPORT
    snippet: Mitral valve prolapse was present in 7.5% and thoracic aortic dilatation in 15.2%.
    explanation: This study reports the presence of mitral valve prolapse in patients with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorder (HSD).
  - reference: PMID:6993166
    reference_title: "Mitral valve prolapse."
    supports: SUPPORT
    snippet: It appears to occur more frequently in females and occasionally it is familial... particularly Marfan's syndrome, rheumatic heart disease, coronary heart disease, congestive cardiomyopathy, ostium secundum atrial septal defect, Ehlers-Danlos syndrome or abnormalities of the thoracic cage.
    explanation: This reference mentions the association of mitral valve prolapse with Ehlers-Danlos syndrome.
  - reference: PMID:34776077
    reference_title: "The Heart Muscle and Valve Involvement in Marfan Syndrome, Loeys-Dietz Syndromes, and Collagenopathies."
    supports: SUPPORT
    snippet: There is substantial symptoms overlap between the EDS subtypes, and they are associated with an increased incidence of cardiovascular abnormalities, such as mitral valve prolapse and aortic dissection.
    explanation: This study confirms the association of mitral valve prolapse with Ehlers-Danlos syndrome.
  - reference: PMID:31328377
    reference_title: "Utilization of echocardiography in Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: Mitral valve prolapse and bicuspid aortic valve occurred at the same incidence as the general population.
    explanation: Indicates no excess incidence versus general population, providing only partial support for phenotype inclusion.
  phenotype_term:
    preferred_term: Mitral Valve Prolapse
    term:
      id: HP:0001634
      label: Mitral valve prolapse
- category: Cardiovascular
  frequency: VERY_FREQUENT
  name: Arterial Dissection and Rupture
  subtype: Vascular EDS
  evidence:
  - reference: PMID:19462862
    reference_title: "[Vascular Ehlers-Danlos syndrome]."
    supports: SUPPORT
    snippet: The mutation of the COL3A1 gene which encodes type III collagen, is responsible of early vascular (spontaneous arterial rupture or dissection)...
    explanation: The abstract explicitly mentions that spontaneous arterial rupture or dissection is a characteristic of vascular Ehlers-Danlos syndrome (vEDS).
  - reference: PMID:23657781
    reference_title: "Embolization of life-threatening arterial rupture in patients with vascular Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: The indication of embolization was spontaneous arterial rupture or pseudoaneurysm with acute bleeding.
    explanation: The study evaluates the treatment of life-threatening arterial rupture in vEDS patients, indicating that arterial rupture is a significant and frequent concern in this subtype.
  - reference: PMID:7455751
    reference_title: "Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: Of the six subtypes of Ehlers-Danlos syndrome, which can usually be clinically differentiated, only types 1 and 4 appear to be associated with a substantial risk of arterial rupture.
    explanation: This reference highlights that type IV Ehlers-Danlos syndrome (vascular EDS) has a substantial risk of arterial rupture.
  - reference: PMID:30999998
    reference_title: "Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study."
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos syndrome (vEDS) is a rare genetic connective tissue disorder secondary to pathogenic variants within the COL3A1 gene, resulting in exceptional arterial and organ fragility and premature death.
    explanation: The abstract indicates that vEDS leads to exceptional arterial fragility, which supports the statement that arterial dissection and rupture are very frequent in this subtype.
  - reference: PMID:33641388
    reference_title: "Spontaneous Cervical Artery Dissection in Vascular Ehlers-Danlos Syndrome: A Cohort Study."
    supports: SUPPORT
    snippet: Arterial complications can affect all anatomic areas and about 25% involve supra-aortic trunks (SATs)...Cumulative incidence of a first identification of a SAT lesion was 41.7% at 40 years old.
    explanation: The study shows a high prevalence of arterial complications, including dissections, in patients with vEDS, supporting the statement.
- category: Gastrointestinal
  frequency: OCCASIONAL
  name: Gastroesophageal Reflux
  review_notes: Added this gastrointestinal manifestation seen in some EDS patients.
  evidence:
  - reference: PMID:26376608
    reference_title: "Ehlers Danlos syndrome and gastrointestinal manifestations: a 20-year experience at Mayo Clinic."
    supports: NO_EVIDENCE
    snippet: 'Commonest GI symptoms were: abdominal pain (56.1%), nausea (42.3%), constipation (38.6%), heartburn (37.6%), and irritable bowel syndrome-like symptoms (27.5%).'
    explanation: The literature mentions heartburn and various other gastrointestinal symptoms but does not specifically mention gastroesophageal reflux as an occasional manifestation.
  - reference: PMID:36000988
    reference_title: "Enrichment of Patients With Ehlers Danlos Syndrome in Idiopathic Gastroparesis-A Gene Set Enrichment Analysis."
    supports: NO_EVIDENCE
    snippet: We report a significant enrichment of EDS cases in a set of patients with gastroparesis.
    explanation: The literature focuses on gastroparesis in EDS patients but does not provide evidence for gastroesophageal reflux as an occasional manifestation.
  - reference: PMID:34811894
    reference_title: "Respiratory manifestations in the Ehlers-Danlos syndromes."
    supports: PARTIAL
    snippet: Functional aerodigestive manifestations such as inducible laryngeal obstruction may be misdiagnosed as asthma, with gastro-esophageal dysmotility and reflux as common contributing factors.
    explanation: The literature mentions gastro-esophageal dysmotility and reflux as contributing factors but does not specify the frequency as 'occasional.'
  phenotype_term:
    preferred_term: Gastroesophageal Reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
- category: Ophthalmologic
  frequency: OCCASIONAL
  name: Keratoconus
  evidence:
  - reference: PMID:36237549
    reference_title: "Ehlers-Danlos syndromes and their manifestations in the visual system."
    supports: PARTIAL
    snippet: In addition to these commonly recognized phenotypes, recent studies have notably highlighted variable ophthalmic features in EDS.
    explanation: Supports ophthalmic variability generally, but only partially supports keratoconus specifically.
  - reference: PMID:34501218
    reference_title: "Controversy and Consideration of Refractive Surgery in Patients with Heritable Disorders of Connective Tissue."
    supports: PARTIAL
    snippet: Because many patients with HDCTs have ocular symptoms, commonly myopia, they will often present to the clinic seeking refractive surgery. Currently, corrective measures are limited, as the FDA contraindicates laser-assisted in-situ keratomileusis (LASIK) in EDS and discourages the procedure in OI and MFS due to a theoretically increased risk of post-LASIK ectasia, poor wound healing, poor refractive predictability, underlying keratoconus, and globe rupture.
    explanation: Provides indirect refractive-surgery caution context and only partial support for keratoconus frequency claim.
  phenotype_term:
    preferred_term: Keratoconus
    term:
      id: HP:0000563
      label: Keratoconus
- category: Musculoskeletal
  name: Recurrent Joint Dislocations
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Recurrent Joint Dislocations
    term:
      id: HP:0001382
      label: Joint hypermobility
- category: Musculoskeletal
  name: Chronic Joint Pain
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Chronic Joint Pain
    term:
      id: HP:0002829
      label: Arthralgia
- category: Musculoskeletal
  name: Decreased Bone Density
  frequency: VERY_FREQUENT
  notes: Systematic review across 839 cases reported decreased bone density prevalence of 90.7%.
  phenotype_term:
    preferred_term: Decreased Bone Density
    term:
      id: HP:0004349
      label: Reduced bone mineral density
- category: Musculoskeletal
  name: Hypotonia
  frequency: FREQUENT
  subtype: Kyphoscoliotic EDS
  notes: Hypotonia and muscular weakness reported in 56.4% of cases across EDS subtypes, particularly prominent in kyphoscoliotic EDS.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
biochemical:
- name: Collagen Type III
  presence: Decreased or Abnormal
  subtype: Vascular EDS
  evidence:
  - reference: PMID:23645670
    reference_title: "Vascular Ehlers-Danlos syndrome mutations in type III collagen differently stall the triple helical folding."
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos syndrome (EDS) type IV is the most severe form of EDS. In many cases the disease is caused by a point mutation of Gly in type III collagen.
    explanation: This reference indicates that vascular Ehlers-Danlos syndrome (EDS) type IV is caused by mutations in type III collagen, supporting the statement about the abnormal presence of collagen type III in this subtype.
  - reference: PMID:35245290
    reference_title: "Comparative therapeutic strategies for preventing aortic rupture in a mouse model of vascular Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos syndrome is a rare inherited disorder caused by genetic variants in type III collagen. Its prognosis is especially hampered by unpredictable arterial ruptures and there is no therapeutic consensus.
    explanation: This reference clearly indicates that the vascular subtype of Ehlers-Danlos syndrome is caused by variants in type III collagen, supporting the statement.
  - reference: PMID:34226255
    reference_title: "Vascular Ehlers-Danlos syndrome presenting in the ICU as aneurysmal subarachnoid haemorrhage."
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos syndrome is caused by mutations of COL3A1 gene coding for type III collagen. The main clinical features involve a propensity to arterial tears leading to several life-threatening conditions and intensive care unit admission.
    explanation: This reference again confirms that vascular Ehlers-Danlos syndrome is tied to abnormalities in type III collagen due to mutations in the COL3A1 gene.
  - reference: PMID:37187299
    reference_title: "Patient-derived extracellular matrix demonstrates role of COL3A1 in blood vessel mechanics."
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos Syndrome (vEDS) is a rare autosomal dominant disease caused by mutations in the COL3A1 gene, which renders patients susceptible to aneurysm and arterial dissection and rupture.
    explanation: The reference supports the link between vascular Ehlers-Danlos Syndrome and abnormalities in collagen type III due to COL3A1 gene mutations.
genetic:
- name: COL1A1
  association: Pathogenic Variants
  subtype: Classical EDS
  evidence:
  - reference: PMID:36896471
    reference_title: "COL1A1 and COL1A2 variants in Ehlers-Danlos syndrome phenotypes and COL1-related overlap disorder."
    supports: SUPPORT
    snippet: Pathogenic variants in COL1A1 and COL1A2 are involved in osteogenesis imperfecta (OI) and, rarely, Ehlers-Danlos syndrome (EDS) subtypes and OI-EDS overlap syndromes (OIEDS1 and OIEDS2, respectively).
    explanation: This statement supports that pathogenic variants in COL1A1 are associated with some subtypes of Ehlers-Danlos Syndrome (EDS).
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "COL1A1 | collagen type I alpha 1 chain | hgnc:2197 | Disease-causing germline mutation(s) in"
    explanation: Orphanet lists COL1A1 as a disease-causing germline gene association for Classical EDS.
- name: COL3A1
  association: Pathogenic Variants
  subtype: Vascular EDS
  evidence:
  - reference: PMID:34560710
    reference_title: "Vascular Ehlers-Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches."
    supports: SUPPORT
    snippet: vEDS patients are at risk of blood vessel rupture due to possession of pathogenic variants of the COL3A1 gene, which encodes type III collagen.
    explanation: The literature explicitly states that vascular Ehlers-Danlos syndrome (vEDS) is caused by pathogenic variants in the COL3A1 gene.
  - reference: PMID:30837697
    reference_title: "Atypical COL3A1 variants (glutamic acid to lysine) cause vascular Ehlers-Danlos syndrome with a consistent phenotype of tissue fragility and skin hyperextensibility."
    supports: SUPPORT
    snippet: Vascular EDS (vEDS) is caused by pathogenic variants in COL3A1, most frequently glycine substitutions.
    explanation: The abstract confirms the association of vascular EDS with pathogenic variants in the COL3A1 gene.
  - reference: PMID:35699227
    reference_title: "Carriers of COL3A1 pathogenic variants in Denmark: Interfamilial variability in severity and outcome of elective surgical procedures."
    supports: SUPPORT
    snippet: Carriers of pathogenic or likely pathogenic COL3A1 variants were retrospectively identified through registries and specialized clinics.
    explanation: The study supports the association between pathogenic COL3A1 variants and vascular Ehlers-Danlos syndrome.
- name: COL5A1
  association: Pathogenic Variants
  subtype: Classical EDS
  evidence:
  - reference: PMID:16278879
    reference_title: "Molecular genetics in classic Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: Mutations in the COL5A1 and the COL5A2 gene, encoding the alpha1 and the alpha2-chain of type V collagen respectively, are identified in approximately 50% of patients with a clinical diagnosis of classic EDS.
    explanation: The reference clearly states that mutations in the COL5A1 gene are associated with classical Ehlers-Danlos Syndrome, thus supporting the statement.
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "COL5A1 | collagen type V alpha 1 chain | hgnc:2209 | Disease-causing germline mutation(s) in"
    explanation: Orphanet lists COL5A1 as a disease-causing germline gene association for Classical EDS.
- name: COL5A2
  association: Pathogenic Variants
  subtype: Classical EDS
  evidence:
  - reference: PMID:16278879
    reference_title: "Molecular genetics in classic Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: Mutations in the COL5A1 and the COL5A2 gene, encoding the alpha1 and the alpha2-chain of type V collagen respectively, are identified in approximately 50% of patients with a clinical diagnosis of classic EDS.
    explanation: The reference confirms that mutations in the COL5A2 gene, encoding the alpha2-chain of type V collagen, are associated with classical EDS and account for approximately 50% of classic EDS cases along with COL5A1.
  - reference: ORPHA:287
    reference_title: "Classical Ehlers-Danlos syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "COL5A2 | collagen type V alpha 2 chain | hgnc:2210 | Disease-causing germline mutation(s) in"
    explanation: Orphanet lists COL5A2 as a disease-causing germline gene association for Classical EDS.
- name: ADAMTS2
  association: Pathogenic Variants
  subtype: Dermatosparaxis EDS
  notes: Loss of procollagen N-proteinase activity leads to failure to remove N-propeptides, resulting in defective fibrillogenesis and fragile skin.
  evidence:
  - reference: PMID:12646579
    reference_title: "Transforming growth factor-beta induces secretion of activated ADAMTS-2. A procollagen III N-proteinase."
    supports: SUPPORT
    snippet: mutations in the ADAMTS-2 gene in dermatosparaxis and Ehlers-Danlos syndrome VIIC show this enzyme to be responsible in vivo for most biosynthetic processing of procollagen I N-propeptides in skin.
    explanation: This study demonstrates that ADAMTS2 mutations cause Ehlers-Danlos syndrome type VIIC (dermatosparaxis) by disrupting procollagen processing.
- name: TNXB
  association: Pathogenic Variants
  subtype: Classical-like EDS
  notes: Tenascin-X deficiency causes defective ECM organization and altered cell-matrix interactions, leading to pain via TLR5-mediated A-fiber hypersensitivity.
  evidence:
  - reference: PMID:36108117
    reference_title: "TNXB-Related Classical-Like Ehlers-Danlos Syndrome."
    supports: SUPPORT
    snippet: The diagnosis of TNXB-related clEDS is established in a proband with suggestive clinical findings and biallelic pathogenic variants in TNXB identified by molecular genetic testing.
    explanation: This GeneReviews entry confirms that biallelic pathogenic variants in TNXB cause classical-like EDS.
- name: C1R
  association: Pathogenic Variants
  subtype: Periodontal EDS
  notes: Mutations lead to intracellular activation of C1r/C1s proteases causing extracellular collagen degradation.
  evidence:
  - reference: PMID:36960056
    reference_title: "Degradation of collagen I by activated C1s in periodontal Ehlers-Danlos Syndrome."
    supports: SUPPORT
    snippet: pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex.
    explanation: This study demonstrates that C1R mutations cause periodontal EDS by triggering intracellular activation of complement proteases.
- name: C1S
  association: Pathogenic Variants
  subtype: Periodontal EDS
  notes: Mutations result in activated C1s protease that degrades collagen I, leading to periodontal tissue destruction and ECM instability.
  evidence:
  - reference: PMID:36960056
    reference_title: "Degradation of collagen I by activated C1s in periodontal Ehlers-Danlos Syndrome."
    supports: SUPPORT
    snippet: pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex.
    explanation: This study demonstrates that C1S mutations cause periodontal EDS, with activated C1s degrading collagen I.
- association: Pathogenic Variants
  name: PLOD1
  subtype: Kyphoscoliotic EDS
  review_notes: Added an additional gene (PLOD1) known to be associated with Kyphoscoliotic EDS as an example of a less common subtype.
  evidence:
  - reference: PMID:32174067
    reference_title: "Rare Cases of PLOD1-Related Kyphoscoliotic Ehlers-Danlos Syndrome in a Korean Family Identified by Next Generation Sequencing."
    supports: SUPPORT
    snippet: Kyphoscoliotic Ehlers-Danlos syndrome (kEDS) is an autosomal recessive connective tissue disorder... The disorder results from a deficiency of the enzyme collagen lysyl hydroxylase 1 due to mutations in the gene PLOD1.
    explanation: This source clearly states that pathogenic variants in the PLOD1 gene are responsible for kyphoscoliotic Ehlers-Danlos syndrome.
  - reference: PMID:15979919
    reference_title: "Mutation analysis of the PLOD1 gene: an efficient multistep approach to the molecular diagnosis of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA)."
    supports: SUPPORT
    snippet: The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA) is an inheritable connective tissue disorder characterized by a deficiency of lysyl hydroxylase due to mutations in PLOD1.
    explanation: This reference supports the association between PLOD1 mutations and kyphoscoliotic Ehlers-Danlos syndrome.
  - reference: PMID:29982180
    reference_title: "Arterial fragility in kyphoscoliotic Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: Pathogenic variants in the lysyl-hydroxylase-1 gene (PLOD1) are responsible for the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS).
    explanation: This source reinforces the role of PLOD1 pathogenic variants in causing kyphoscoliotic Ehlers-Danlos syndrome.
  - reference: PMID:36054293
    reference_title: "Kyphoscoliotic Ehlers-Danlos syndrome caused by pathogenic variants in FKBP14: Further insights into the phenotypic spectrum and pathogenic mechanisms."
    supports: SUPPORT
    snippet: 'The autosomal recessive kyphoscoliotic EDS results from deficiency of either lysyl hydroxylase 1 (encoded by PLOD1), crucial for collagen cross-linking... '
    explanation: This study adds further confirmation of the genetic association between PLOD1 and kyphoscoliotic Ehlers-Danlos syndrome.
animal_models:
- species: Mouse
  genotype: Col5a1 knockout
  genes:
  - preferred_term: COL5A1
    term:
      id: hgnc:2209
      label: COL5A1
  associated_phenotypes:
  - Skin hyperextensibility
  - Joint hypermobility
  evidence:
  - reference: PMID:20587693
    reference_title: "The haploinsufficient Col3a1 mouse as a model for vascular Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: The heterozygous Col3a1 knockout mouse was investigated as a model for this disease... thorough histological examination of the aorta of heterozygous mice revealed the presence of a spectrum of lesions similar to those observed in human patients.
    explanation: While this study focused on Col3a1 rather than Col5a1, it provides evidence that knockout models can be used to investigate aspects of vascular Ehlers-Danlos syndrome in mice.
  - reference: PMID:20847697
    reference_title: "Clinical and genetic aspects of Ehlers-Danlos syndrome, classic type."
    supports: PARTIAL
    snippet: It is currently estimated that approximately 50% of patients with a clinical diagnosis of classic Ehlers-Danlos syndrome harbor mutations in the COL5A1 and the COL5A2 gene... the disease is caused by a mutation leading to a nonfunctional COL5A1 allele and resulting in haploinsufficiency of type V collagen.
    explanation: While the study confirms the involvement of COL5A1 mutations in Ehlers-Danlos Syndrome, it does not mention specific phenotype outcomes in animal models. Thus, the support for the proposed mouse model is partial.
  - reference: PMID:35627182
    reference_title: "Independent COL5A1 Variants in Cats with Ehlers-Danlos Syndrome."
    supports: PARTIAL
    snippet: We searched for private protein changing variants in known human EDS candidate genes and identified three independent heterozygous COL5A1 variants.
    explanation: This study identified COL5A1 variants in Ehlers-Danlos Syndrome cases among cats, contributing to the understanding of COL5A1 mutations. However, it does not describe a mouse model specifically, making the support only partial.
- species: Mouse
  genotype: Col3a1 heterozygous
  genes:
  - preferred_term: COL3A1
    term:
      id: hgnc:2201
      label: COL3A1
  associated_phenotypes:
  - Vascular fragility
  - Arterial rupture
  evidence:
  - reference: PMID:20587693
    reference_title: "The haploinsufficient Col3a1 mouse as a model for vascular Ehlers-Danlos syndrome."
    supports: SUPPORT
    snippet: Haploinsufficiency for Col3a1 in mice recapitulates features of vascular Ehlers-Danlos syndrome in humans and can be used as an experimental model.
    explanation: The study shows that haploinsufficient Col3a1 mice exhibit reduced collagen content in the aorta and diminishing wall strength, mirroring vascular EDS in humans, which supports the statement.
environmental:
- name: Physical Trauma
  effect: Exacerbates Symptoms
  evidence:
  - reference: PMID:26452443
    reference_title: "Ehlers-Danlos syndrome(s) mimicking child abuse: Is there an impact on clinical practice?"
    supports: SUPPORT
    snippet: Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas.
    explanation: The snippet indicates that minor physical trauma can exacerbate symptoms by causing severe mucocutaneous injuries in EDS patients.
  - reference: PMID:28186390
    reference_title: "Pain management in the Ehlers-Danlos syndromes."
    supports: NO_EVIDENCE
    snippet: Pain, which is often one of the first symptoms to occur, may be widespread or localized to one region such as an arm or a leg
    explanation: Snippet does not directly address physical trauma as an environmental exacerbating factor.
  - reference: PMID:23095510
    reference_title: "Gastrointestinal surgery and related complications in patients with Ehlers-Danlos syndrome: a systematic review."
    supports: PARTIAL
    snippet: Optimal therapy for these patients includes the awareness that EDS is a systemic disease involving fragility, bleeding and spontaneous perforations from almost all organ systems.
    explanation: Supports systemic fragility and complication risk, but only partially supports explicit trauma-exacerbation framing.
- effect: Exacerbates Symptoms
  name: Repetitive Motion
  review_notes: Added based on domain knowledge as repetitive motion is often a factor in exacerbating symptoms for connective tissue disorders.
  evidence:
  - reference: PMID:31582002
    reference_title: "Symptomatic Joint Hypermobility: The Hypermobile Type of Ehlers-Danlos Syndrome and the Hypermobility Spectrum Disorders."
    supports: PARTIAL
    snippet: Symptomatic joint hypermobility can result from soft tissue injury or muscular strain caused by muscular imbalance.
    explanation: Supports strain/injury context in hypermobility, but only partially supports repetitive-motion environmental effect claim.
  - reference: PMID:32175940
    reference_title: "A review of Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: Thirteen EDS subtypes are recognized, with a wide degree of symptom overlap among subtypes and with other connective tissue disorders.
    explanation: Although it discusses the overlap of symptoms, it does not directly state that repetitive motion exacerbates these symptoms. However, it implies increased fragility and susceptibility, which could be worsened by repetitive motion.
treatments:
- name: Supportive Care
  description: Management of pain, physical therapy to strengthen joints, and prevention of complications.
  evidence:
  - reference: PMID:38189943
    reference_title: "Treating pain in patients with Ehlers-Danlos syndrome : Multidisciplinary management of a multisystemic disease."
    supports: SUPPORT
    snippet: Affected patients require multimodal pain management considering their individual needs, disease-specific features, and comorbidities.
    explanation: This reference highlights the need for multimodal pain management in Ehlers-Danlos syndrome (EDS) patients, which is a component of supportive care.
  - reference: PMID:34145717
    reference_title: "Physical therapy treatment of hypermobile Ehlers-Danlos syndrome: A systematic review."
    supports: SUPPORT
    snippet: Physiotherapy benefits on proprioception and pain in patients with hEDS even if robust randomized control studies are missing.
    explanation: This reference supports the use of physical therapy, which strengthens joints and manages pain, aligning with the statement.
  - reference: PMID:17067502
    reference_title: "Ehlers-Danlos syndrome in athletes."
    supports: PARTIAL
    snippet: Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active.
    explanation: Supports multidisciplinary screening/management context, but only partially supports the full supportive-care treatment claim.
  - reference: PMID:32941194
    reference_title: "Current management of the vascular subtype of Ehlers-Danlos syndrome."
    supports: PARTIAL
    snippet: The creation of multidisciplinary care teams and tertiary referral centers is helping improve outcomes.
    explanation: Supports multidisciplinary care framework, but only partially supports specific supportive-care interventions listed.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Surgical Interventions
  description: May be needed for severe joint instability or life-threatening complications like arterial dissections.
  evidence:
  - reference: PMID:32904109
    reference_title: "Surgical Management of Shoulder and Knee Instability in Patients with Ehlers-Danlos Syndrome: Joint Hypermobility Syndrome."
    supports: SUPPORT
    snippet: Patients with joint hypermobility syndrome (JHS) might also present with similar symptomatology. This article will focus on the surgical management of patients with knee or shoulder abnormalities related to hEDS/JHS.
    explanation: This article supports the need for surgical interventions for severe joint instability in patients with hypermobile Ehlers-Danlos Syndrome, which can be considered analogous to severe cases in other types of EDS.
  - reference: PMID:30999998
    reference_title: "Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study."
    supports: NO_EVIDENCE
    snippet: The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality... During the period surveyed, the authors observed a statistically significant difference in the ratio of hospitalizations for acute arterial events/hospitalizations for regular follow-up before and after 2011.
    explanation: Snippet is pharmacologic trial context and does not directly support surgical intervention.
  - reference: PMID:33650410
    reference_title: "Ehlers-Danlos Syndrome Type IV - Anaesthetic Considerations."
    supports: PARTIAL
    snippet: The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences.
    explanation: Supports life-threatening complication profile, but only indirectly supports surgical treatment recommendation.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Lifestyle Modifications
  description: Avoiding high-impact activities and contact sports to prevent injury.
  evidence:
  - reference: PMID:17067502
    reference_title: "Ehlers-Danlos syndrome in athletes."
    supports: PARTIAL
    snippet: Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active.
    explanation: Supports screening/management in athletes, but only partially supports explicit avoidance recommendation.
  - reference: PMID:35756986
    reference_title: "Exercise and Rehabilitation in People With Ehlers-Danlos Syndrome: A Systematic Review."
    supports: PARTIAL
    snippet: The results suggest that exercise and rehabilitation may be beneficial for various physical and psychological outcomes.
    explanation: Supports exercise/rehabilitation benefit generally, but only partial support for avoiding high-impact/contact sports specifically.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
- description: Use of orthotic devices to support unstable joints.
  name: Orthotic Interventions
  review_notes: Added orthotic interventions commonly recommended in the management of EDS.
  evidence:
  - reference: PMID:27349123
    reference_title: "Ehlers-Danlos-Tschernogobow : Histoire contrarlée de la maladie."
    supports: PARTIAL
    snippet: ignorance of effective treatments such as oxygen therapy and orthotics are new concepts that should shake the prejudices derived from the history of this disease.
    explanation: Provides limited support for orthotics; phrasing is broad and indirect.
  - reference: PMID:32709178
    reference_title: "Ehlers-Danlos Syndrome: An Analysis of the Current Treatment Options."
    supports: SUPPORT
    snippet: Occupational therapy and bracing were the most effective options with 70% of patients reporting improvement.
    explanation: This reference supports the use of orthotic devices (e.g., bracing) as effective in the management of EDS.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
review_notes: Overall, filled in some additional phenotypes based on the example schema for a more complete clinical picture. The original record seems focused on the severe vascular subtype, but I generalized it to capture manifestations across EDS subtypes.
disease_term:
  preferred_term: Ehlers-Danlos syndrome
  term:
    id: MONDO:0020066
    label: Ehlers-Danlos syndrome
classifications:
  harrisons_chapter:
  - classification_value: musculoskeletal system disorder
  - classification_value: connective tissue disease
  - classification_value: hereditary disease
  mechanistic_category:
  - classification_value: collagenopathy
references:
- reference: PMID:36108117
  title: "TNXB-Related Classical-Like Ehlers-Danlos Syndrome."
  tags:
  - GeneReviews
  findings: []
- reference: PMID:20301635
  title: "PLOD1-Related Kyphoscoliotic Ehlers-Danlos Syndrome."
  tags:
  - GeneReviews
  findings: []
- reference: PMID:20301456
  title: "Hypermobile Ehlers-Danlos Syndrome."
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

3

PMID:36108117

TNXB-Related Classical-Like Ehlers-Danlos Syndrome.

No top-level findings curated for this source.

PMID:20301635

PLOD1-Related Kyphoscoliotic Ehlers-Danlos Syndrome.

No top-level findings curated for this source.

PMID:20301456

Hypermobile Ehlers-Danlos Syndrome.

No top-level findings curated for this source.

Deep Research

3

Disorder ▸

Disorder

Name: Ehlers-Danlos Syndrome
Category: Genetic
Existing deep-research providers: falcon, perplexity
Existing evidence reference count in YAML: 124

Key Pathophysiology Nodes

Collagen Abnormalities
Connective Tissue Fragility
Tissue Injury and Dysfunction
Integrin-Mediated Mechanotransduction Dysregulation
Autophagy and Proteostasis Dysfunction
Complement-Mediated ECM Degradation
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1002/(sici)1097-0177(200006)218:2%3c235::aid-dvdy2%3e3.0.co
DOI:10.1002/ajmg.a.63857
DOI:10.1002/ajmg.a.63957
DOI:10.1002/humu.24456
DOI:10.1016/j.isci.2024.110676
DOI:10.1038/s41598-023-45638-7
DOI:10.1101/2023.03.24.23287706
DOI:10.1101/2025.09.19.25336146
DOI:10.1152/physrev.00003.2017
DOI:10.1515/medgen-2024-2060
DOI:10.1515/medgen-2024-2061
DOI:10.3389/fgene.2021.717535
DOI:10.3389/fgene.2023.1136339
DOI:10.3389/fimmu.2019.02537
DOI:10.3389/fimmu.2023.1157421
DOI:10.3389/fmed.2023.1053466
DOI:10.3390/biom14040472
DOI:10.3390/biomedicines12122749
DOI:10.3390/cimb46030166
PMID:27745832
PMID:31409039
PMID:32162201
PMID:34807422
PMID:37827202
PMID:38183136
PMID:40972649
PMID:7378285

Falcon ▸

Disease Pathophysiology Research Report

Edison Scientific Literature 26 citations 2025-12-15T09:23:06.393079

Disease Pathophysiology Research Report

Target Disease - Disease Name: Ehlers-Danlos Syndrome (EDS) - MONDO ID: [not specified] - Category: Genetic

Pathophysiology overview EDS comprises a group of heritable connective tissue disorders with subtype-specific molecular etiologies that converge on extracellular matrix (ECM) dysfunction. Established monogenic subtypes arise from defects in fibrillar collagens or their processing, cross-linking, folding, or ECM regulatory proteins; periodontal EDS uniquely reflects dysregulated complement protease activity. Hypermobile EDS (hEDS) remains genetically unresolved and likely reflects complex polygenic/regulatory mechanisms affecting ECM, neuroimmune signaling, pain, and autonomic function (see details below) (zschocke2024geneticdiagnosisof pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3, wilson2024clinicalgenomicanalysisof pages 17-19, wilson2023agenenetwork pages 19-21).

1) Core pathophysiology - Primary mechanisms across subtypes - Collagen fibrillogenesis defects: classical EDS (cEDS; COL5A1/COL5A2) reduces type V collagen, impairing type I fibril nucleation/organization; vascular EDS (vEDS; COL3A1) weakens type III–rich vessels; dermatosparaxis EDS (dEDS; ADAMTS2) impairs procollagen N-propeptide removal; kyphoscoliotic EDS (kEDS; PLOD1/FKBP14) compromises collagen cross-linking (PLOD1) and folding (FKBP14); classical-like EDS (clEDS; TNXB) disrupts ECM organization and cell–matrix mechanics; GAG-biosynthesis EDS (spEDS; B4GALT7/B3GALT6/B3GAT3) alters proteoglycan linker assembly and growth-factor signaling; AEBP1-related clEDS2 alters ECM assembly (zschocke2024geneticdiagnosisof pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3). - Complement-driven ECM degradation in periodontal EDS (pEDS; C1R/C1S): intracellular activation of C1r/C1s yields extracellular activated C1s that degrades collagen I and destabilizes ECM (“pathogenesis in pEDS is not solely mediated by activation of the complement cascade but by inadequate C1s-mediated degradation of matrix proteins”) (Frontiers in Immunology, 2023; DOI: 10.3389/fimmu.2023.1157421) (pliegoarreaga2024jointhypermobilitysyndrome pages 5-6). - Complex/polygenic mechanisms in hEDS: GWAS/meta-analytic and clinical-genomic studies implicate regulatory loci (e.g., near ACKR3), SLC39A13/ZIP13, neuroimmune/pain pathways, and autonomic/immune networks, supporting a “neuroimmune–stromal” disease model (preprint; medRxiv 2025) and a clinically derived “articulo–autonomic gene network” (2024) (petruccinelson2025complexgeneticsand pages 11-14, wilson2024clinicalgenomicanalysisof pages 17-19, wilson2023agenenetwork pages 19-21).

Dysregulated molecular pathways (selected)
ECM organization, fibril assembly, integrin signaling (e.g., αvβ3 upregulation), and inflammatory programs (e.g., IL-1β) in cEDS; targeting αvβ3 partially rescues wound healing in Col5a1-deficient mouse wounds (iScience, 2024; DOI: 10.1016/j.isci.2024.110676) (kellyscumpia2024modulatingtheextracellular pages 6-8).
vEDS dermal fibroblasts show integrated proteomic/transcriptomic abnormalities implicating impaired ECM organization, autophagy–lysosome pathways, cellular stress responses, and miRNA regulation (e.g., miR-29b-3p), with miR-29b-3p inhibition increasing type V and I collagen (Biomedicines, 2024) (zschocke2024geneticdiagnosisof pages 5-6).
pEDS illustrates complement–ECM crosstalk: activated C1s enzymatically degrades collagen I in vitro and in patient fibroblast matrices (Frontiers in Immunology, 2023) (pliegoarreaga2024jointhypermobilitysyndrome pages 5-6).
clEDS (TNXB) pain mechanisms: TNX-deficient mice exhibit mechanical allodynia mediated by A-fiber hypersensitivity and constitutive TLR5 signaling (Scientific Reports, 2023) ().
Affected cellular processes
Procollagen processing (ADAMTS2), collagen cross-link formation (PLOD1), ER folding/isomerization (FKBP14), ECM gene regulation (miRNAs, ZNF469/PRDM5), complement activation (C1R/C1S), integrin mechanosignaling, autophagy/proteostasis, and neuroimmune–nociceptive signaling (ACKR3/neuroimmune axes) (zschocke2024geneticdiagnosisof pages 5-6, kellyscumpia2024modulatingtheextracellular pages 6-8, pliegoarreaga2024jointhypermobilitysyndrome pages 5-6, petruccinelson2025complexgeneticsand pages 11-14).

2) Key molecular players - Genes/proteins (HGNC; representative) - cEDS: COL5A1, COL5A2 (type V collagen) (kellyscumpia2024modulatingtheextracellular pages 6-8, doolan2023extracutaneousfeaturesand pages 2-3) - vEDS: COL3A1 (type III collagen) (zschocke2024geneticdiagnosisof pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3) - hEDS: unresolved; regulatory loci (ACKR3), SLC39A13/ZIP13 implicated (preprint) (petruccinelson2025complexgeneticsand pages 11-14) - pEDS: C1R, C1S (classical complement C1 proteases; activated C1s degrades collagen I) (pliegoarreaga2024jointhypermobilitysyndrome pages 5-6) - kEDS: PLOD1 (lysyl hydroxylase 1), FKBP14 (ER PPIase) (zschocke2024geneticdiagnosisof pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3) - dEDS: ADAMTS2 (procollagen I/II N-proteinase) (doolan2023extracutaneousfeaturesand pages 2-3) - clEDS: TNXB (tenascin‑X; anti-adhesive ECM glycoprotein) (doolan2023extracutaneousfeaturesand pages 2-3) - clEDS2: AEBP1 (ECM-associated) (doolan2023extracutaneousfeaturesand pages 2-3) - spEDS: B4GALT7, B3GALT6, B3GAT3 (GAG linker biosynthesis) (doolan2023extracutaneousfeaturesand pages 2-3) - BCS: ZNF469, PRDM5 (ECM gene regulation in cornea) (zschocke2024geneticdiagnosisof pages 5-6) - Additional modifier/regulatory candidates: miR-29b-3p (vEDS fibroblasts), integrins (αvβ3), inflammatory cytokines (IL‑1β), TLR5 (TNXB model) (zschocke2024geneticdiagnosisof pages 5-6, kellyscumpia2024modulatingtheextracellular pages 6-8).

Chemical entities (CHEBI; examples)
Collagens and ECM proteins; integrin antagonists (e.g., cilengitide) tested in model systems; complement proteases (serine proteases C1r/C1s); cytokines (IL‑1β) (kellyscumpia2024modulatingtheextracellular pages 6-8, pliegoarreaga2024jointhypermobilitysyndrome pages 5-6).
Cell types (CL) and anatomical locations (UBERON)
Dermal fibroblasts (CL:0000057), vascular smooth muscle cells (CL:0000187), endothelial cells (CL:0000115), peripheral sensory neurons (CL:0000103), myofibroblasts (CL:0001059). Key tissues: skin dermis (UBERON:0002067), arterial wall (UBERON:0001981), periodontal tissues (UBERON:0004114), corneal stroma (UBERON:0001772), fascia/tendon/ligament (UBERON:0001987/0001338/0002076) (kellyscumpia2024modulatingtheextracellular pages 6-8, zschocke2024geneticdiagnosisof pages 5-6, pliegoarreaga2024jointhypermobilitysyndrome pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3).

3) Biological processes for GO annotation (selected) - Extracellular matrix organization; collagen fibril organization; collagen biosynthetic process; procollagen N‑terminal propeptide cleavage; collagen cross-linking; protein folding (ER); integrin-mediated signaling pathway; regulation of inflammatory response; complement activation, classical pathway; autophagy; cellular response to mechanical stimulus; regulation of neuron projection development; sensory perception of pain (zschocke2024geneticdiagnosisof pages 5-6, kellyscumpia2024modulatingtheextracellular pages 6-8, pliegoarreaga2024jointhypermobilitysyndrome pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3, wilson2024clinicalgenomicanalysisof pages 17-19, wilson2023agenenetwork pages 19-21).

4) Cellular components (selected) - Extracellular matrix; collagen fibril; basement membrane; ER lumen; Golgi apparatus; lysosome/autophagosome; plasma membrane integrin complexes; complement C1 complex (zschocke2024geneticdiagnosisof pages 5-6, kellyscumpia2024modulatingtheextracellular pages 6-8, pliegoarreaga2024jointhypermobilitysyndrome pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3).

5) Disease progression (sequence of events; subtype examples) - cEDS (COL5A1/2): type V collagen deficiency → impaired type I fibrillogenesis and ECM disarray → altered mechanotransduction (αvβ3 upregulation) and persistent dermal inflammation (↑IL‑1β) → poor wound tensile strength, atrophic scarring, skin hyperextensibility and joint instability. Direct experimental evidence: “Col5a1 conditional KO wounds show fibrillar disarray, increased αvβ3 and IL‑1β, reduced mechanical strength,” with pharmacologic αvβ3 antagonism or WT fibroblasts partially rescuing healing (iScience, 2024; DOI: 10.1016/j.isci.2024.110676) (kellyscumpia2024modulatingtheextracellular pages 6-8). - vEDS (COL3A1): mutant type III collagen → fragile arterial/organ ECM → fibroblast proteome/transcriptome shows impaired ECM organization, autophagy–lysosome and stress responses; miR‑29b‑3p inhibition restores ECM proteins (Biomedicines, 2024) → clinical arterial dissection/rupture and aneurysm (zschocke2024geneticdiagnosisof pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3). - pEDS (C1R/C1S): intracellular activation of C1r/C1s → extracellular activated C1s (aC1s) → collagen I degradation and high collagen turnover → unstable periodontal/CT matrix → severe early-onset periodontitis, thin fragile gums; frequent white-matter changes suggest small-vessel involvement (Frontiers in Immunology, 2023; Frontiers in Genetics, 2023) (pliegoarreaga2024jointhypermobilitysyndrome pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3). - clEDS (TNXB): tenascin‑X deficiency → disordered ECM and altered cell–matrix adhesion → peripheral A‑fiber hypersensitivity via constitutive TLR5 activation → mechanical allodynia and neuropathic pain (Scientific Reports, 2023) (). - hEDS: complex regulatory variation (e.g., ACKR3 enhancer; SLC39A13 locus) → neuroimmune–stromal dysregulation and altered nociception, autonomic imbalance, gastrointestinal and pain comorbidities; integrated clinical-genomic networks link connective tissue laxity to autonomic/neuromuscular features (medRxiv 2025 preprint; Current Issues in Molecular Biology, 2024) (petruccinelson2025complexgeneticsand pages 11-14, wilson2024clinicalgenomicanalysisof pages 17-19, wilson2023agenenetwork pages 19-21).

6) Phenotypic manifestations and quantitative data - Systematic review across 839 cases reported: - Joint hypermobility prevalence: kyphoscoliotic 100% (39/39), spEDS 96.0% (24/25), hEDS 95.6% (153/160) (Frontiers in Medicine, 2023; DOI: 10.3389/fmed.2023.1053466) (doolan2023extracutaneousfeaturesand pages 2-3). - Musculoskeletal complications: decreased bone density 90.7% (39/43), joint pain 80.4% (217/270), hypotonia/weakness 56.4% (79/140) (doolan2023extracutaneousfeaturesand pages 2-3). - vEDS vascular outcomes: cerebrovascular events 16.3% (25/153), aneurysm 31.4% (77/245), arterial dissection/rupture 35.5% (89/250) (doolan2023extracutaneousfeaturesand pages 2-3). - Direct quotes highlighting mechanisms - pEDS: “pathogenesis in pEDS is not solely mediated by activation of the complement cascade but by inadequate C1s-mediated degradation of matrix proteins, confirming pEDS as a primary connective tissue disorder” (Frontiers in Immunology, 2023; DOI: 10.3389/fimmu.2023.1157421) (pliegoarreaga2024jointhypermobilitysyndrome pages 5-6). - cEDS (mouse model): Col5a1-deficient wounds show “increased αvβ3 and IL-1β,” fibrillar disarray, and reduced mechanical strength; αvβ3 antagonism or WT fibroblasts partially rescue healing (iScience, 2024; DOI: 10.1016/j.isci.2024.110676) (kellyscumpia2024modulatingtheextracellular pages 6-8). - clEDS pain: “mechanical allodynia due to TNX deficiency is caused by the hypersensitivity of Aδ- and Aβ-fibers, and it is induced by constitutive activation of TLR5” (Scientific Reports, 2023; DOI: 10.1038/s41598-023-45638-7) ().

Recent developments and latest research (2023–2024 priority) - cEDS: in vivo mechanobiology of COL5A1 deficiency establishes αvβ3/IL‑1β signaling as wound-healing modulators and demonstrates partial rescue by integrin antagonism or fibroblast therapy (iScience, 2024) (kellyscumpia2024modulatingtheextracellular pages 6-8). - vEDS: patient-fibroblast multi-omics highlights miRNA (miR‑29b‑3p)–mediated control of ECM and autophagy–lysosome pathways; miR‑29b‑3p inhibition restores collagen I/V expression (Biomedicines, 2024) (zschocke2024geneticdiagnosisof pages 5-6). Clinical reviews reinforce vigilance for arterial events and outline prevention strategies (2024) (doolan2023extracutaneousfeaturesand pages 2-3). - pEDS: mechanistic confirmation that aC1s degrades collagen I and accelerates matrix turnover in patient fibroblasts, providing a direct link between complement proteases and ECM fragility (Frontiers in Immunology, 2023) (pliegoarreaga2024jointhypermobilitysyndrome pages 5-6). Clinical series emphasize leukoencephalopathy (white-matter changes) in adults with C1R variants (Frontiers in Genetics, 2023) (doolan2023extracutaneousfeaturesand pages 2-3). - clEDS (TNXB): murine models connect ECM deficiency to nociceptive pathway sensitization via TLR5 (Scientific Reports, 2023) (). - hEDS: convergent evidence for complex, multisystem pathogenesis involving neuroimmune–stromal regulation and shared genetic correlations with pain, autonomic, and GI disorders; clinical-genomic networks identify autonomic and neuromuscular linkages (2024; preprint 2025) (wilson2024clinicalgenomicanalysisof pages 17-19, petruccinelson2025complexgeneticsand pages 11-14, wilson2023agenenetwork pages 19-21).

Current applications and real-world implementations - Molecular diagnosis: 12 of 13 subtypes have identifiable monogenic causes and are amenable to panel/exome testing; structural variants (e.g., PLOD1 duplication, TNXB/RCCX rearrangements) may require long-range methods (Medizinische Genetik, 2024; DOI: 10.1515/medgen-2024-2061) (zschocke2024geneticdiagnosisof pages 5-6). - Clinical surveillance: systematic review data support high rates of joint hypermobility, musculoskeletal morbidity, and vEDS vascular events, reinforcing routine vascular imaging and risk reduction (Frontiers in Medicine, 2023) (doolan2023extracutaneousfeaturesand pages 2-3). - Emerging targeted concepts: - ECM-modulating therapeutics in cEDS wound repair (integrin αvβ3 antagonists; cell therapy) (iScience, 2024) (kellyscumpia2024modulatingtheextracellular pages 6-8). - miRNA modulation (miR‑29b‑3p) and autophagy–lysosome pathways in vEDS fibroblasts (Biomedicines, 2024) (zschocke2024geneticdiagnosisof pages 5-6). - Protease/complement modulation in pEDS (targeting aberrant aC1s activity) (Frontiers in Immunology, 2023) (pliegoarreaga2024jointhypermobilitysyndrome pages 5-6).

Expert opinions and authoritative analyses - Diagnostic framework: “Pathogenesis is related to disturbances of collagen formation and/or stability… No monogenic cause has been identified for hypermobile EDS (hEDS), … unlikely to represent a single gene disorder” (Medizinische Genetik, 2024; DOI: 10.1515/medgen-2024-2061) (zschocke2024geneticdiagnosisof pages 5-6). - Network view: An “articulo–autonomic gene network” links tissue laxity, autonomic imbalance, and neuromuscular dysfunction, supporting polygenic and pathway-level interpretation—consistent with multisystem clinical expression (Current Issues in Molecular Biology, 2024; DOI: 10.3390/cimb46030166) (wilson2024clinicalgenomicanalysisof pages 17-19).

Relevant statistics and data from recent studies - Extracutaneous burden (2023 systematic review; n=839): joint hypermobility up to 100% in kEDS, 96% in spEDS, 95.6% in hEDS; decreased bone density 90.7%; joint pain 80.4%; hypotonia 56.4% (Frontiers in Medicine, 2023; DOI: 10.3389/fmed.2023.1053466) (doolan2023extracutaneousfeaturesand pages 2-3). - vEDS vascular outcomes (same review): cerebrovascular 16.3%, aneurysm 31.4%, arterial dissection/rupture 35.5% (doolan2023extracutaneousfeaturesand pages 2-3). - Experimental (cEDS mouse wounds): significant reductions in mechanical strength and collagen content with elevated αvβ3 and IL‑1β; partial pharmacologic rescue (iScience, 2024; DOI: 10.1016/j.isci.2024.110676) (kellyscumpia2024modulatingtheextracellular pages 6-8).

Structured subtype summary (2023–2024 evidence prioritized)

Subtype	Gene(s) (HGNC)	Primary mechanism	Key pathways	Affected tissues / cell types	Hallmark phenotypes (HP terms)	Selected recent mechanistic evidence (2023–2024) with DOI/URL	Therapeutic implications
cEDS (classical)	COL5A1, COL5A2	Type V collagen haploinsufficiency → defective collagen I/V fibrillogenesis, abnormal fibril nucleation & organization	ECM organization, TGF-β signalling, integrin (αvβ3) mediated cell–matrix signalling	Dermal fibroblasts, epidermis, tendon/ligament ECM, skin dermis	Skin hyperextensibility, atrophic scarring, joint hypermobility (HP:0001382, HP:0000969)	Kelly-Scumpia et al., 2024: Col5a1 conditional KO wounds show fibrillar disarray, increased αvβ3 and IL-1β, reduced mechanical strength (iScience 2024) https://doi.org/10.1016/j.isci.2024.110676 (kellyscumpia2024modulatingtheextracellular pages 6-8, doolan2023extracutaneousfeaturesand pages 2-3)	ECM-modulating strategies: integrin αvβ3 antagonists (cilengitide in models), fibroblast cell therapy, wound-focused approaches (kellyscumpia2024modulatingtheextracellular pages 6-8)
vEDS (vascular)	COL3A1	Mutant type III collagen → weakened arterial/organ walls; abnormal fibril assembly and ECM homeostasis	ECM/vascular integrity, PLC/IP3/PKC/ERK signalling dysregulation, proteostasis/autophagy, miRNA regulation	Vascular smooth muscle cells, endothelial cells, dermal fibroblasts, arterial ECM	Arterial/organ rupture, aneurysm, thin translucent skin (HP:0000826, HP:0004942)	Chiarelli et al., 2024: integrative proteomics/transcriptomics in vEDS fibroblasts implicates impaired ECM organization, autophagy and miR-29b-3p; miR-29b-3p inhibition restored ECM proteins (Biomedicines 2024) https://doi.org/10.3390/biomedicines12122749 (zschocke2024geneticdiagnosisof pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3)	Vascular surveillance; blood-pressure control (celiprolol evidence discussed 2024); emerging molecular targets: ERK/PKC pathway and miRNA modulation (zschocke2024geneticdiagnosisof pages 5-6, wilson2024clinicalgenomicanalysisof pages 17-19)
hEDS (hypermobile; genetically unresolved)	— (no single-gene HGNC)	Complex, likely polygenic/regulatory; ECM fragility + neuroimmune–stromal dysregulation; altered cell–matrix adhesion	Neuroimmune signaling, nociception/pain pathways, zinc/metal transport (SLC39A13), inflammation, mechanotransduction	Dermal/fascial fibroblasts, peripheral nerves (small fibers), autonomic neurons, musculoskeletal fascia	Generalized joint hypermobility, chronic pain, dysautonomia/POTS, fatigue (HP:0001382, HP:0001249, HP:0001278)	GWAS/meta (preprint) and clinical-genomic studies propose regulatory loci (ACKR3) and SLC39A13 implicating neuroimmune–stromal model; Petrucci-Nelson et al. (preprint, 2025) & Wilson/Tonk clinical-genomic analyses (2024) propose polygenic/regulatory drivers (petruccinelson2025complexgeneticsand pages 11-14, wilson2024clinicalgenomicanalysisof pages 17-19, wilson2023agenenetwork pages 19-21)	Symptom-directed multidisciplinary care (pain, rehab, autonomic management); research on neuroimmune modulators, zinc/metal homeostasis and fascia-targeted therapies (petruccinelson2025complexgeneticsand pages 11-14, wilson2024clinicalgenomicanalysisof pages 17-19)
pEDS (periodontal)	C1R, C1S	Gain-of-function intracellular activation of C1r/C1s → extracellular activated C1s protease degrades ECM (collagen I) → periodontal/connective-tissue destruction	Classical complement activation, protease-mediated ECM degradation, inflammation	Gingival fibroblasts, periodontal ECM, small vessels, neural tissue (leukoencephalopathy in cohorts)	Early severe periodontitis, tooth loss, pretibial plaques, easy bruising (HP:0000674, HP:0000209)	Amberger et al., 2023: activated C1s degrades collagen I in vitro and patient fibroblasts → destabilized ECM; Angwin et al., 2023: pEDS associated with white-matter changes; DOI: 10.3389/fimmu.2023.1157421, https://doi.org/10.3389/fgene.2023.1136339 (pliegoarreaga2024jointhypermobilitysyndrome pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3)	Dental surveillance, periodontal management; potential approaches targeting aberrant complement activation or protease activity (pliegoarreaga2024jointhypermobilitysyndrome pages 5-6)
kEDS-PLOD1 (kyphoscoliotic)	PLOD1	Lysyl hydroxylase (LH1) deficiency → impaired hydroxylysine formation → defective collagen cross-linking and unstable fibrils	Collagen post-translational modification, cross-linking, ECM stability	Skin, ligaments, bone matrix, muscle connective tissue	Congenital hypotonia, progressive kyphoscoliosis, joint laxity (HP:0001251, HP:0002948)	Diagnostic/mechanistic synthesis in reviews and genetic-diagnosis updates (Zschocke 2024; transcriptome distinctions noted in prior studies) (zschocke2024geneticdiagnosisof pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3)	Orthopedic/rehab management; genetic counseling; research into stabilizing cross-link pathways and tailored supportive care (zschocke2024geneticdiagnosisof pages 5-6)
kEDS-FKBP14 (kyphoscoliotic)	FKBP14	ER-localized peptidyl-prolyl isomerase dysfunction → impaired collagen folding/secretion → abnormal ECM	ER protein folding, collagen biosynthesis, ECM assembly	Fibroblasts, muscle connective tissue, tendon ECM	Kyphoscoliosis, hypotonia, joint laxity, myopathy (HP:0002948, HP:0001251)	Cohort and mechanistic literature summarised in reviews and genetic-diagnosis updates (zschocke2024geneticdiagnosisof pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3)	Supportive orthopedic care; potential exploration of chaperone/ER-stress modulating strategies in research (zschocke2024geneticdiagnosisof pages 5-6)
dEDS (dermatosparaxis)	ADAMTS2	Loss of procollagen N-proteinase activity → failure to remove N-propeptides → defective fibrillogenesis, fragile skin	Procollagen processing, ECM protease activity, collagen fibrillogenesis	Dermal fibroblasts, skin ECM	Skin fragility, cutaneous tears, abnormal collagen ultrastructure (HP:0001593)	ADAMTS2 pathogenicity established across species (animal/veterinary reports) and case reports; ADAMTS2 functional links summarized in classical reviews (Malfait 2014; recent animal/case reports) (sciclunaUnknownyearthegeneticsof pages 20-25, doolan2023extracutaneousfeaturesand pages 2-3)	Wound care, surgical precautions; potential future protease-replacement or ECM-targeting therapies (doolan2023extracutaneousfeaturesand pages 2-3)
clEDS (classical-like; TNXB)	TNXB	Tenascin‑X deficiency → defective ECM organization, altered collagen–cell interactions and dysregulated MMP clearance (via THBS2 interactions)	ECM organization, MMP regulation, cell–matrix adhesion, TLR5-linked neuronal sensitization (pain)	Dermis, fascia, peripheral nerves, blood vessels	Skin hyperextensibility without atrophic scarring, joint hypermobility, chronic pain, neuropathy (HP:0001382, HP:0001388)	Okuda-Ashitaka 2023 and Kamada 2023: TNX-deficient mice show mechanical allodynia via A-fiber/TLR5 hypersensitivity; Hadar et al., 2024: THBS2 variant causes vascular-like EDS via MMP2 dysregulation (sciclunaUnknownyearthegeneticsofb pages 25-27, wilson2024clinicalgenomicanalysisof pages 17-19)	Pain-targeted strategies; attention to neuropathic mechanisms (A-fibre sensitization); research into MMP modulation and matricellular protein pathways (wilson2024clinicalgenomicanalysisof pages 17-19)
clEDS2 (AEBP1-related)	AEBP1	ECM scaffolding/collagen-associated protein defects → abnormal collagen assembly and ECM maintenance	ECM assembly, transcriptional regulation of matrix components	Skin, connective tissues, dermal fibroblasts	Skin hyperextensibility, joint hypermobility, poor wound healing (HP:0001382, HP:0001593)	AEBP1 bi-allelic alterations described in recent clinical cohorts and reviews linking AEBP1 to collagen assembly (cited in systematic reviews) (doolan2023extracutaneousfeaturesand pages 2-3, dijk2024clinicaldiagnosisof pages 3-4)	Supportive care and surveillance; research into ECM-restorative strategies (dijk2024clinicaldiagnosisof pages 3-4)
spEDS (spondylodysplastic; GAG-biosynthesis forms)	B4GALT7, B3GALT6, B3GAT3	Defects in glycosaminoglycan (GAG) linker synthesis → abnormal proteoglycan/heparan-sulfate assembly → altered ECM signalling and structure	GAG biosynthesis, growth-factor sequestration/signalling, ECM–cell signalling	Cartilage, bone, skin ECM, tendon	Short stature, radiologic skeletal dysplasia, hypermobile joints (HP:0004322, HP:0001382)	Systematic/genetic reviews and case series document GAG-biosynthesis gene effects on skeletal/connective development (doolan2023extracutaneousfeaturesand pages 2-3, sciclunaUnknownyearthegeneticsof pages 20-25)	Orthopedic/skeletal management; potential interest in modifying GAG-related signalling in future research (doolan2023extracutaneousfeaturesand pages 2-3)
BCS (Brittle Cornea Syndrome)	ZNF469, PRDM5	Transcriptional regulators of ECM/collagen gene programs → corneal thinning and ECM fragility	ECM gene regulation, collagen biosynthesis, ocular ECM maintenance	Corneal stroma, ocular connective tissues, dermal ECM	Keratoconus, corneal thinning, ocular rupture risk (HP:0000592, HP:0000557)	Genetic/clinical summaries and reviews noting ZNF469/PRDM5 regulation of ECM and corneal phenotype; discussed in genetic-diagnosis literature (zschocke2024geneticdiagnosisof pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3)	Ophthalmologic surveillance, protective measures; molecular studies target ECM regulatory pathways (zschocke2024geneticdiagnosisof pages 5-6)

Table: Compact summary table of major Ehlers–Danlos subtypes showing genes, core molecular mechanisms, affected tissues, hallmark phenotypes, 2023–2024 mechanistic evidence (DOI/URL), and therapeutic implications; useful as an at-a-glance reference for knowledgebase curation and research planning.

Ontology-linked annotations for knowledge base - Genes/proteins (HGNC): COL5A1/COL5A2 (cEDS), COL3A1 (vEDS), C1R/C1S (pEDS), PLOD1/FKBP14 (kEDS), ADAMTS2 (dEDS), TNXB (clEDS), AEBP1 (clEDS2), B4GALT7/B3GALT6/B3GAT3 (spEDS), ZNF469/PRDM5 (BCS); candidate/regulatory: ACKR3, SLC39A13 (hEDS, emerging) (zschocke2024geneticdiagnosisof pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3, petruccinelson2025complexgeneticsand pages 11-14). - GO Biological Processes: extracellular matrix organization; collagen fibril organization; collagen biosynthetic process; procollagen N‑terminal peptidase activity; collagen cross-linking; protein folding; complement activation, classical pathway; integrin-mediated signaling; autophagy; inflammatory response; sensory perception of pain (kellyscumpia2024modulatingtheextracellular pages 6-8, pliegoarreaga2024jointhypermobilitysyndrome pages 5-6, zschocke2024geneticdiagnosisof pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3). - GO Cellular Components: extracellular matrix; collagen trimer/fibril; basement membrane; ER lumen; Golgi apparatus; autophagosome/lysosome; integrin complex; complement C1 complex (zschocke2024geneticdiagnosisof pages 5-6, kellyscumpia2024modulatingtheextracellular pages 6-8, pliegoarreaga2024jointhypermobilitysyndrome pages 5-6). - Phenotype associations (HP): generalized joint hypermobility (HP:0001382), skin hyperextensibility (HP:0000974), atrophic scarring (HP:0001075; not typical in clEDS), arterial aneurysm (HP:0002617), arterial rupture (HP:0002642), early periodontitis (HP:0000674), white-matter abnormalities (HP:0002539) (doolan2023extracutaneousfeaturesand pages 2-3, pliegoarreaga2024jointhypermobilitysyndrome pages 5-6). - Cell types (CL): dermal fibroblast (CL:0000057), vascular smooth muscle cell (CL:0000187), endothelial cell (CL:0000115), myofibroblast (CL:0001059), peripheral sensory neuron (CL:0000103) (kellyscumpia2024modulatingtheextracellular pages 6-8, zschocke2024geneticdiagnosisof pages 5-6). - Anatomical locations (UBERON): skin dermis (UBERON:0002067), arterial wall (UBERON:0001981), periodontal tissue (UBERON:0004114), corneal stroma (UBERON:0001772), tendon/ligament (UBERON:0001987/0002076) (doolan2023extracutaneousfeaturesand pages 2-3, pliegoarreaga2024jointhypermobilitysyndrome pages 5-6). - Chemical entities (CHEBI): collagen, integrin antagonists (e.g., cilengitide), complement serine proteases (C1r/C1s), cytokines (IL‑1β) (kellyscumpia2024modulatingtheextracellular pages 6-8, pliegoarreaga2024jointhypermobilitysyndrome pages 5-6).

Evidence items with links (recent priority) - Kelly‑Scumpia KM et al. Modulating the extracellular matrix to treat wound healing defects in Ehlers‑Danlos syndrome. iScience. 2024-09. DOI: 10.1016/j.isci.2024.110676. URL: https://doi.org/10.1016/j.isci.2024.110676 (cEDS, integrin/IL‑1β) (kellyscumpia2024modulatingtheextracellular pages 6-8). - Chiarelli N et al. Integrative Multi‑Omics Approach in Vascular Ehlers–Danlos Syndrome… Biomedicines. 2024-11. DOI: 10.3390/biomedicines12122749. URL: https://doi.org/10.3390/biomedicines12122749 (vEDS, miR‑29b‑3p/autophagy) (zschocke2024geneticdiagnosisof pages 5-6). - Amberger A et al. Degradation of collagen I by activated C1s in periodontal EDS. Front Immunol. 2023-03. DOI: 10.3389/fimmu.2023.1157421. URL: https://doi.org/10.3389/fimmu.2023.1157421 (pEDS, C1s proteolysis) (pliegoarreaga2024jointhypermobilitysyndrome pages 5-6). - Doolan BJ et al. Extracutaneous features and complications of the EDS: a systematic review. Front Med. 2023-01. DOI: 10.3389/fmed.2023.1053466. URL: https://doi.org/10.3389/fmed.2023.1053466 (quantitative burden) (doolan2023extracutaneousfeaturesand pages 2-3). - Zschocke J et al. Genetic diagnosis of the EDS. Medizinische Genetik. 2024-11. DOI: 10.1515/medgen-2024-2061. URL: https://doi.org/10.1515/medgen-2024-2061 (diagnostic genes/subtypes) (zschocke2024geneticdiagnosisof pages 5-6). - Kamada H et al. Hypersensitivity of myelinated A‑fibers via TLR5 promotes mechanical allodynia in tenascin‑X‑deficient mice. Sci Rep. 2023-10. DOI: 10.1038/s41598-023-45638-7. URL: https://doi.org/10.1038/s41598-023-45638-7 (clEDS pain) (). - Wilson GN & Tonk VS. Clinical‑Genomic Analysis of 1261 Patients with EDS outlines an Articulo‑Autonomic Gene Network. Curr Issues Mol Biol. 2024-03. DOI: 10.3390/cimb46030166. URL: https://doi.org/10.3390/cimb46030166 (network model) (wilson2024clinicalgenomicanalysisof pages 17-19). - Petrucci‑Nelson T et al. Complex Genetics and Regulatory Drivers of hEDS (GWAS meta‑analysis). medRxiv. 2025-09 (preprint). DOI: 10.1101/2025.09.19.25336146. URL: https://doi.org/10.1101/2025.09.19.25336146 (regulatory/neuroimmune model) (petruccinelson2025complexgeneticsand pages 11-14).

Conclusion and future directions EDS pathophysiology reflects convergent ECM failure with subtype-specific mechanisms—collagen fibrillogenesis and cross-link defects, procollagen processing deficits, complement protease overactivity, and dysregulated mechanobiology and autophagy—with growing evidence for neuroimmune–stromal mechanisms in hEDS. Recent experimental advances (2023–2024) provide tractable targets: integrin αvβ3 and inflammatory mediators in cEDS wound healing; miRNA/autophagy in vEDS fibroblasts; complement protease activity in pEDS; and TLR5-mediated A‑fiber sensitization in clEDS. Translating these into therapies will require controlled trials, mechanistically matched biomarkers, and integration with vigilant clinical surveillance and multidisciplinary care (kellyscumpia2024modulatingtheextracellular pages 6-8, zschocke2024geneticdiagnosisof pages 5-6, pliegoarreaga2024jointhypermobilitysyndrome pages 5-6, doolan2023extracutaneousfeaturesand pages 2-3, wilson2024clinicalgenomicanalysisof pages 17-19).

References

(zschocke2024geneticdiagnosisof pages 5-6): Johannes Zschocke, Serwet Demirdas, and Fleur S. van Dijk. Genetic diagnosis of the ehlers-danlos syndromes. Medizinische Genetik, 36:235-245, Nov 2024. URL: https://doi.org/10.1515/medgen-2024-2061, doi:10.1515/medgen-2024-2061. This article has 3 citations and is from a poor quality or predatory journal.
(doolan2023extracutaneousfeaturesand pages 2-3): Brent J. Doolan, Mark E. Lavallee, Ingrid Hausser, Jane R. Schubart, F. Michael Pope, Suranjith L. Seneviratne, Ingrid M. Winship, and Nigel P. Burrows. Extracutaneous features and complications of the ehlers-danlos syndromes: a systematic review. Frontiers in Medicine, Jan 2023. URL: https://doi.org/10.3389/fmed.2023.1053466, doi:10.3389/fmed.2023.1053466. This article has 23 citations and is from a poor quality or predatory journal.
(wilson2024clinicalgenomicanalysisof pages 17-19): Golder N. Wilson and Vijay S. Tonk. Clinical-genomic analysis of 1261 patients with ehlers–danlos syndrome outlines an articulo-autonomic gene network (entome). Current Issues in Molecular Biology, 46:2620-2643, Mar 2024. URL: https://doi.org/10.3390/cimb46030166, doi:10.3390/cimb46030166. This article has 8 citations and is from a poor quality or predatory journal.
(wilson2023agenenetwork pages 19-21): Golder N. Wilson. A gene network implicated in the joint-muscle pain, brain fog, chronic fatigue, and bowel irregularity of ehlers-danlos and "long" covid19 syndromes. MedRxiv, Mar 2023. URL: https://doi.org/10.1101/2023.03.24.23287706, doi:10.1101/2023.03.24.23287706. This article has 1 citations.
(pliegoarreaga2024jointhypermobilitysyndrome pages 5-6): Raquel Pliego-Arreaga, Juan Antonio Cervantes-Montelongo, Guillermo Antonio Silva-Martínez, Fabiola Estefanía Tristán-Flores, Miguel Angel Pantoja-Hernández, and Juan Raúl Maldonado-Coronado. Joint hypermobility syndrome and membrane proteins: a comprehensive review. Biomolecules, 14:472, Apr 2024. URL: https://doi.org/10.3390/biom14040472, doi:10.3390/biom14040472. This article has 6 citations and is from a poor quality or predatory journal.
(petruccinelson2025complexgeneticsand pages 11-14): Taylor Petrucci-Nelson, Sacha Guilhaumou, Takiy E Berrandou, Cortney Gensemer, Adrien Georges, Matthew Huff, Margaux-Alison Fustier, Asraa Esmael, Josephine Henry, Olivia Jaye, Ranan Phookan, Sarah Dooley, Kathryn Byerly, Brian Loizzi, Roman Fenner, Emma Mach, Amy Weintraub, Victoria Daylor, Julianna Weninger, Natalie Koren, Erika Bistran, Charlotte Griggs, Molly Griggs, Sydney Severance, Rebecca Byrd, Sunil Patel, Steven A Kautz, Anne Maitland, Nabila Bouatia-Naji, and Russell A Norris. Complex genetics and regulatory drivers of hypermobile ehlers-danlos syndrome: insights from genome-wide association study meta-analysis. MedRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.19.25336146, doi:10.1101/2025.09.19.25336146. This article has 0 citations.
(kellyscumpia2024modulatingtheextracellular pages 6-8): Kindra M. Kelly-Scumpia, Maani M. Archang, Prabhat K. Purbey, Tomohiro Yokota, Rimao Wu, Jackie McCourt, Shen Li, Rachelle H. Crosbie, Philip O. Scumpia, and Arjun Deb. Modulating the extracellular matrix to treat wound healing defects in ehlers-danlos syndrome. iScience, 27:110676, Sep 2024. URL: https://doi.org/10.1016/j.isci.2024.110676, doi:10.1016/j.isci.2024.110676. This article has 5 citations and is from a peer-reviewed journal.
(sciclunaUnknownyearthegeneticsof pages 20-25): K Scicluna. The genetics of hypermobile ehlers-danlos syndrome: a local study. Unknown journal, Unknown year.
(sciclunaUnknownyearthegeneticsofb pages 25-27): K Scicluna. The genetics of hypermobile ehlers-danlos syndrome: a local study. Unknown journal, Unknown year.
(dijk2024clinicaldiagnosisof pages 3-4): Fleur S. van Dijk, Chloe Angwin, Serwet Demirdas, Neeti Ghali, and Johannes Zschocke. Clinical diagnosis of the monogenic ehlers-danlos syndromes. Medizinische Genetik, 36:225-234, Nov 2024. URL: https://doi.org/10.1515/medgen-2024-2060, doi:10.1515/medgen-2024-2060. This article has 1 citations and is from a poor quality or predatory journal.

Perplexity ▸

Comprehensive Pathophysiology of Ehlers-Danlos Syndrome: Molecular Mechanisms, Cellular Dysfunction, and Multi-System Complications

sonar-deep-research 56 citations 2025-12-16T06:41:17.021391

This is a comprehensive request for a research report on the pathophysiology of Ehlers-Danlos Syndrome (EDS). The user wants me to cover:

Core pathophysiology and molecular mechanisms
Key molecular players (genes, proteins, cell types, anatomical locations)
Biological processes affected
Cellular components involved
Disease progression
Phenotypic manifestations

I have extensive search results provided that cover these topics in detail. Let me plan my approach:

Main Sections I should include: 1. Introduction/Executive Summary 2. Overview of EDS classification and genetic basis 3. Core Pathophysiological Mechanisms - organized by major type or mechanism 4. Molecular Players and Key Genes 5. Cellular and Subcellular Mechanisms 6. ECM Dysregulation and Organization 7. Type-Specific Pathophysiology (Classical, Vascular, Hypermobile) 8. Multi-system Involvement and Complications 9. Conclusion with therapeutic implications

Key points to cover from sources: - EDS classified into 13 subtypes with 19 causal genes (from [1][4]) - Primarily affects collagen synthesis/processing and ECM maintenance - Classical EDS (cEDS): COL5A1/COL5A2 mutations affecting type V collagen - Vascular EDS (vEDS): COL3A1 mutations affecting type III collagen
- Hypermobile EDS (hEDS): molecular basis unknown, immune dysregulation emerging - ER stress, autophagy dysfunction, protein misfolding issues - Wound healing defects - Vascular complications in vEDS - Immune dysfunction in hEDS - Central sensitization and pain pathways - Autonomic dysfunction - Mast cell involvement

I need to write at least 10,000 words in narrative format (no bullet points), with proper citations throughout.

Comprehensive Pathophysiology of Ehlers-Danlos Syndrome: Molecular Mechanisms, Cellular Dysfunction, and Multi-System Complications

Ehlers-Danlos syndrome (EDS) represents a complex and heterogeneous group of heritable connective tissue disorders affecting approximately one in five thousand individuals worldwide, though this prevalence may be an underestimate given recent diagnostic advances[1]. The pathophysiology of EDS involves fundamental disruptions in extracellular matrix (ECM) biology, with the 2017 nosology recognizing 13 distinct subtypes caused by pathogenic variants in 19 different genes that primarily affect collagen synthesis, processing, and organization, as well as the structural integrity and function of associated ECM components[1][4]. Beyond the well-characterized structural defects in collagen, emerging evidence reveals that EDS pathophysiology encompasses complex dysregulation of endoplasmic reticulum (ER) homeostasis, autophagy, immune function, nociceptive pain pathways, and vascular integrity, making this a multifaceted disease that affects virtually every organ system. This comprehensive review synthesizes current molecular and cellular understanding of EDS pathophysiology, integrating recent discoveries in transcriptomics, proteomics, and systems-level analysis to illuminate how genetic mutations in connective tissue components cascade into the diverse clinical manifestations characteristic of this disorder.

Fundamental Genetic Architecture and Classification of Ehlers-Danlos Syndrome

The genetic basis of EDS reflects the central importance of the extracellular matrix in tissue integrity and homeostasis. The 2017 classification system organizes EDS subtypes into functional groups based on the underlying molecular defect, with Group A disorders affecting the primary structure and processing of collagen, Group B disorders affecting collagen folding and crosslinking, and Group C disorders involving intracellular processes and other ECM-related disturbances[1][4]. The most prevalent subtypes include classical EDS (cEDS), vascular EDS (vEDS), and hypermobile EDS (hEDS), which together account for the majority of diagnosed cases, though rare subtypes such as kyphoscoliotic EDS (kEDS), periodontal EDS (pEDS), spondylodysplastic EDS (spEDS), and dermatosparaxis EDS (dEDS) display distinct genetic etiologies and pathophysiological mechanisms. Classical EDS is typically caused by heterozygous mutations in COL5A1 or COL5A2, encoding the proα1(V) and proα2(V) chains of type V collagen, respectively, with an estimated worldwide prevalence of one in twenty thousand[3]. Vascular EDS, the most life-threatening subtype, results from heterozygous mutations predominantly in COL3A1 encoding type III collagen, and less commonly in COL1A1[3][13]. In contrast, hypermobile EDS, the most common variant, currently lacks identified causal genes in the majority of cases, suggesting genetic heterogeneity or oligogenic inheritance patterns that remain to be fully elucidated[1]. The recent discovery that kyphoscoliotic EDS can result from pathogenic variants in FKBP14, encoding a molecular chaperone for collagen folding, exemplifies how continued molecular investigation reveals new mechanistic insights into connective tissue biology[15]. This genetic diversity underscores the complexity of connective tissue assembly and maintenance, with different gene products contributing to various aspects of ECM formation, processing, stability, and homeostasis.

Core Pathophysiological Mechanisms: Collagen Synthesis, Processing, and Extracellular Matrix Organization

The fundamental pathophysiology of EDS originates from defective production, processing, or structural integrity of collagen molecules, the most abundant protein in the human body and a primary structural component of the ECM across virtually all tissues. In classical EDS caused by COL5A1 or COL5A2 mutations, the primary defect involves reduced availability of type V collagen, a quantitatively minor but structurally critical component that nucleates the assembly and organization of type I collagen fibrils[1][6]. Studies of dermal fibroblasts from cEDS patients demonstrate that the majority of affected individuals harbor COL5A1 haploinsufficiency due to mRNA transcript instability, with approximately 29.5 percent of cEDS cases characterized by decreased expression of one COL5A1 allele[6]. The mutations underlying COL5A1 haploinsufficiency include nonsense mutations, splice site mutations, and insertion-deletions that destabilize transcripts through mechanisms such as nonsense-mediated decay, resulting in production of collagen V at insufficient levels to properly direct type I collagen fibrillogenesis[6]. In vascular EDS, mutations in COL3A1 typically involve glycine substitutions within the triple helical domain that disrupt the characteristic Gly-X-Y amino acid repeat pattern essential for triple helix formation and stability[2][7]. These glycine substitutions in the collagen III triple helix result in misfolded procollagen III molecules that misfold in the endoplasmic reticulum, impairing their secretion and deposition into the ECM, thereby reducing the availability of functionally mature type III collagen[2]. The defective collagen molecules that are produced often exhibit abnormal assembly into fibrils with irregular diameters, disorganized architecture, and compromised mechanical properties, features documented through transmission electron microscopy analysis of affected tissues[1][7].

Beyond the primary collagen defects, the pathophysiology of EDS involves complex dysregulation of the entire extracellular matrix ecosystem. Proteomic and transcriptomic analyses of skin fibroblasts from vEDS patients reveal widespread dysregulation of extracellular matrix components characterized by upregulation of multiple collagen types and other ECM proteins, suggesting compensation mechanisms that paradoxically recapitulate features reminiscent of fibrosis[7][10]. In vEDS fibroblasts, the expression and activity of lysyl oxidase (LOX), the cupro-enzyme that initiates covalent crosslinking of collagen and elastin molecules through lysine oxidation, is elevated compared to controls, and correspondingly, levels of the crosslinked form of collagen III (C-telopeptide of collagen III or CTXIII) are significantly increased[10]. This dysregulated ECM turnover in vEDS creates a pathological microenvironment where excessive collagen crosslinking contributes to increased tissue rigidity and a fibrotic phenotype that paradoxically coexists with vascular fragility and tissue weakness. The balance between extracellular effects, such as reduced protein secretion and accumulation of misfolded proteins, and intracellular consequences including ER stress, apoptosis activation, and autophagy perturbation determines the overall molecular pathology and disease severity across different EDS subtypes[2].

Endoplasmic Reticulum Stress and Protein Quality Control Mechanisms

A critical component of EDS pathophysiology involves dysregulation of endoplasmic reticulum (ER) homeostasis and protein quality control mechanisms, reflecting the enormous biosynthetic burden placed on the ER by collagen production. The ER is a fundamental cellular organelle responsible for synthesis, folding, modification, and transport of proteins destined for secretion, functions that are particularly demanding in fibroblasts which synthesize large amounts of collagen[11]. The biosynthesis, processing, and integrity of collagens and other ECM structural constituents are essential for maintaining intracellular proteostasis, a state of cellular protein balance that requires constant surveillance and correction of misfolded proteins[2][11]. Under normal conditions, the ER maintains homeostasis through multiple quality control mechanisms including the unfolded protein response (UPR), endoplasmic reticulum-associated degradation (ERAD), and selective autophagy pathways that together ensure that only properly folded proteins are exported and that potentially harmful misfolded proteins are eliminated[8][11]. In cEDS and vEDS fibroblasts, however, the aberrant production and accumulation of misfolded collagen V and collagen III molecules overwhelms these quality control mechanisms, leading to perturbation of ER homeostasis that manifests as ER stress and activation of UPR signaling[2].

The unfolded protein response, a sophisticated multi-pronged cellular stress response, is activated when misfolded or unfolded proteins accumulate in the ER lumen beyond the capacity of ER chaperone proteins to manage[8][11]. Three major ER-resident sensor proteins—protein kinase RNA-like ER kinase (PERK), inositol-requiring enzyme 1α (IRE1α), and activating transcription factor 6 (ATF6)—detect ER stress through binding of accumulated unfolded proteins, and their activation triggers a cascade of signaling events aimed at restoring ER homeostasis[8][11]. The initial response involves PERK-mediated phosphorylation of eIF2α, which attenuates global protein translation to reduce the protein synthesis burden on the stressed ER, thereby preventing further accumulation of misfolded proteins[8][11]. However, selective translation of ATF4 and the downstream induction of CHOP (C/EBP homologous protein) can lead to prolonged ER stress-induced apoptosis if homeostasis is not rapidly restored[8]. In cEDS fibroblasts, transcriptomic profiling reveals dysregulated expression of genes encoding ER chaperone proteins and components of the ERAD machinery, suggesting that in addition to direct collagen misfolding, the regulatory mechanisms that normally restore ER homeostasis are themselves dysregulated[2]. These perturbations of ER homeostasis contribute to cellular dysfunction beyond simple protein folding defects, potentially triggering inflammatory signaling cascades and altered cell survival dynamics that impact the fibroblast population's capacity to maintain ECM integrity.

Autophagy Dysregulation and Intracellular Protein Accumulation

Complementary to ER stress responses, autophagy represents another critical cellular quality control mechanism that becomes dysregulated in EDS pathophysiology. Autophagy is a fundamental intracellular degradation pathway wherein cellular components including proteins, organelles, and lipids are sequestered within double-membrane vesicles called autophagosomes and delivered to lysosomes for degradation, a process essential for protein homeostasis, metabolism, cell survival, and tissue remodeling[2]. In normal fibroblasts, basal levels of autophagy maintain cellular quality and clear aggregated proteins that escape ER-associated degradation mechanisms; however, in cEDS fibroblasts, this pathway becomes dysregulated as evidenced by accumulation of autophagolysosomes and altered expression of autophagy-related genes[2][15]. Transmission electron microscopy analysis of skin fibroblasts from EDS patients reveals multiple autophagolysosomes, suggesting either increased autophagy initiation coupled with impaired autophagy flux, or alternatively, excessive accumulation of autophagic vesicles due to impaired lysosomal degradation capacity[15]. This autophagy dysregulation appears intertwined with aberrant ER homeostasis, as the two pathways share regulatory mechanisms and can influence each other through processes such as ER-phagy, selective autophagy of ER regions. The crosstalk between ER stress and autophagy dysregulation likely contributes to the complex pathophysiology of EDS, potentially amplifying intracellular stress and triggering pro-inflammatory or pro-apoptotic signaling cascades that further compromise fibroblast function and ECM maintenance.

Integrin Signaling and Cell-Matrix Interactions in Classical and Hypermobile EDS

The integrity of cell-matrix interactions mediated through integrin-based focal adhesions represents another critical level of EDS pathophysiology. Integrins are heterodimeric transmembrane receptors consisting of α and β subunits that serve as the primary mediators of cell attachment to the extracellular matrix, providing both mechanical anchoring and essential biochemical signaling that guides cell behavior, survival, proliferation, and differentiation[2][41]. In healthy fibroblasts, type I collagen engages with the α2β1 integrin while fibronectin binds primarily through the α5β1 integrin, these canonical cell-matrix interactions organizing focal adhesion complexes at the cell periphery that contain dozens of scaffold and signaling proteins including focal adhesion kinase (FAK), integrin-linked kinase (ILK), Src family kinases, paxillin, and vinculin[2][41]. In cEDS fibroblasts, however, comprehensive immunofluorescence studies reveal profound disorganization of the ECM along with coordinated loss of the canonical integrin receptors α2β1 and α5β1[2][41]. This loss of canonical integrin organization is accompanied by a striking compensatory increase in expression and organization of the alternative integrin receptor αvβ3, which localizes to linear patches at both focal and fibrillar adhesions[2][41]. The αvβ3 integrin, while capable of binding to fibronectin and other ECM ligands containing the RGD amino acid motif, triggers a distinct and aberrant signaling cascade through recruitment of different downstream effector proteins including ILK and the transcription factors Snail1/Slug[2][41].

The functional consequences of this integrin switch from canonical α5β1 to the alternative αvβ3 receptor extend far beyond simple mechanical attachment, as the αvβ3 integrin signaling axis drives a fibroblast-to-myofibroblast transition (FMT) characterized by acquisition of contractile proteins including α-smooth muscle actin (α-SMA), reorganization of the actin cytoskeleton into stress fibers, and altered gene expression patterns that promote ECM degradation and perpetuate tissue remodeling[2][21][41]. This myofibroblast-like phenotype, typically associated with wound healing and tissue repair contexts, becomes pathologically sustained in EDS cells through aberrant αvβ3 integrin signaling, creating a feed-forward loop wherein compromised ECM organization reduces canonical integrin signaling, promotes αvβ3 recruitment, and triggers myofibroblast differentiation that further alters ECM composition and organization[2][21]. Studies using conditioned media from hEDS fibroblasts demonstrate that patient-derived secreted factors can transfer this pathological phenotype to control fibroblasts, converting them from normal fibroblasts into ECM-disorganized myofibroblast-like cells, indicating that hEDS cells actively secrete factors promoting ECM dysarray and myofibroblast differentiation[21]. Furthermore, matrix metalloproteinases (MMPs), particularly MMP9, are elevated in hEDS secretions and contribute to excessive degradation of ECM proteins, establishing a detrimental feedback loop whereby dysregulated protease activity degrades remaining functional ECM, perpetuates integrin dysregulation, and sustains myofibroblast differentiation[21].

Type-Specific Pathophysiology: Classical Ehlers-Danlos Syndrome

Classical EDS (cEDS), characterized clinically by skin hyperextensibility, atrophic scarring, and generalized joint hypermobility, displays distinctive pathophysiological mechanisms centered on type V collagen deficiency and its consequences for fibril organization and wound healing[1][3][6]. The deficiency of type V collagen in cEDS results primarily from haploinsufficiency, with approximately 30 percent of cEDS patients carrying null alleles of COL5A1 that produce no functional transcript, while an additional subset harbor missense mutations creating dominant-negative effects through incorporation of abnormal chains into heterotrimeric collagen molecules[6]. Type V collagen plays a disproportionate structural role in collagen fibrillogenesis despite comprising less than 5-10 percent of total collagen mass, functioning as a nucleation template upon which type I collagen molecules assemble into organized fibrils[1][6]. In the absence of sufficient type V collagen, type I collagen fibrils fail to organize into regular arrays with uniform diameters, instead forming haphazardly arranged fibrils with variable and often enlarged diameter distributions and compromised mechanical properties[1][56]. Beyond direct effects on collagen organization, type V collagen deficiency affects multiple aspects of tissue homeostasis through impacts on wound healing and matrix remodeling. Transcriptome profiling of cEDS fibroblasts reveals dysregulated expression of numerous genes encoding matricellular proteins such as osteopontin (SPP1), periostin (POSTN), and EDIL3, which play critical roles in cell-matrix interactions, cell migration, angiogenesis, and tissue remodeling during wound healing[2][38]. The marked downregulation of EDIL3, an ECM-associated protein promoting angiogenesis through integrin binding and regulating neutrophil recruitment to inflamed tissue, suggests impaired capacity for mounting appropriate angiogenic and inflammatory responses during wound repair[2][38].

The wound healing defect in cEDS reflects both the structural abnormalities in collagen fibril organization and dysregulation of the molecular programs governing coordinated wound repair. A recently developed murine model of cEDS employing conditional deletion of Col5a1 in fibroblasts demonstrates that acute loss of type V collagen is sufficient to phenocopy multiple human cEDS pathological features including delayed re-epithelialization, poor ECM organization, enhanced and prolonged inflammation, and tissue-wide dysregulation of integrin expression[56]. In these Col5a1-deficient mice, acute wounds display gross fibrillar disorganization with collagen fibrils running orthogonally to each other in haphazard arrangements rather than the parallel organization observed in wild-type wounds, consistent with observations in human cEDS tissues[56]. The wound healing defect correlates with reduced epidermal gene expression and upregulation of inflammatory gene programs, suggesting that aberrant ECM composition and organization impairs normal keratinocyte migration and amplifies inflammatory responses[56]. Importantly, this model demonstrates that wound healing defects can be partially rescued through either fibroblast transplantation delivering wild-type cells capable of producing normal collagen, or through pharmacological inhibition of integrin signaling using cilengitide, an αvβ3 integrin antagonist, indicating that mechanosensitive integrin signaling dysfunction contributes centrally to cEDS pathophysiology and that this pathway may represent a therapeutic target[56]. The enhanced and prolonged inflammation observed in cEDS wounds correlates with upregulation of integrin expression and aberrant integrin signaling, suggesting that pathological integrin-ECM interactions drive sustained inflammatory responses through altered immune cell recruitment and activation.

Type-Specific Pathophysiology: Vascular Ehlers-Danlos Syndrome

Vascular EDS (vEDS), the most severe and life-threatening EDS subtype, exhibits pathophysiology fundamentally distinct from cEDS despite sharing the common theme of collagen deficiency, reflecting the specialized structural requirements of blood vessel walls. The mutations in COL3A1 characteristic of vEDS predominantly involve glycine substitutions that disrupt the fundamental triple helix structure of type III collagen, the collagen type that comprises the major structural component of blood vessel walls, particularly within the medial and adventitial layers of arteries and hollow organs[13][16]. In contrast to the quantitative deficiency of type V collagen in cEDS, vEDS involves production of structurally defective, misfolded type III collagen molecules that accumulate abnormally in cells and compromise vascular integrity through both qualitative and quantitative mechanisms[2][7]. The defective collagen III molecules accumulate intracellularly due to impaired secretion, suggesting that misfolding in the ER prevents normal export, and the type III collagen that is successfully secreted forms abnormal fibrils and ECM structures that lack the mechanical integrity necessary to withstand arterial hemodynamic stress[2][7]. This pathophysiology manifests clinically in nearly 80 percent of vEDS patients experiencing vascular complications by age 40, including arterial aneurysms, dissections, and ruptures that together account for approximately 92 percent of vEDS-related deaths[13][16]. The median lifespan of vEDS patients is approximately 48 years, reflecting the life-threatening nature of spontaneous vascular rupture that can occur without warning under normal hemodynamic conditions[49].

The vascular fragility in vEDS results from weakened structural integrity of the arterial wall consequent to deficient type III collagen. The adventitial layer of blood vessels, which normally provides structural support and mechanical strength through its collagenous and elastic fiber networks, becomes compromised in vEDS, rendering arteries susceptible to rupture under conditions that would not challenge normal vessels[13][50]. The weakened vascular wall combined with structural abnormalities leads to increased turbulent blood flow and heightened shear stress within affected vessels, particularly at anatomical sites of hemodynamic stress such as the aortic root and the distal aortic arch, where these elevated mechanical forces combine with the compromised structural integrity to promote aneurysm formation and dissection[13][16][50]. Beyond the primary vascular complications, vEDS also predisposes to rupture of hollow organs including the gastrointestinal tract, uterus, and bladder, reflecting the importance of type III collagen throughout connective tissues[13][49][51]. Gastrointestinal perforations account for a significant proportion of vEDS morbidity and mortality, with perforations most commonly involving the colon, particularly the sigmoid colon, occurring at an average age of 24 years with mortality rates reaching 12 percent[51]. These spontaneous perforations result from the fundamental tissue fragility and poor wound healing characteristic of vEDS, wherein compromised collagen structure impairs the mechanical integrity and repair capacity of hollow organ walls. Pregnancy represents a particularly high-risk period in vEDS, with increased uterine rupture risk occurring most frequently during the third trimester when hemodynamic stress on blood vessels increases markedly, creating a scenario where the combination of pregnancy-associated vascular remodeling and underlying vascular fragility from defective type III collagen creates catastrophic risk for spontaneous rupture and maternal death[3].

Type-Specific Pathophysiology: Hypermobile Ehlers-Danlos Syndrome and Immune Dysregulation

Hypermobile EDS (hEDS), the most prevalent EDS subtype accounting for approximately 90 percent of diagnosed cases, presents distinctive pathophysiological mechanisms that differ substantially from classical and vascular subtypes, particularly regarding the apparent absence of identified pathogenic variants in known collagen genes and the emerging recognition of immune dysfunction as a central disease driver[1][12]. The molecular basis of hEDS has remained enigmatic despite intensive genetic investigation, suggesting either genetic heterogeneity with multiple distinct genes contributing to disease, oligogenic inheritance patterns requiring multiple genetic variants for disease manifestation, or incomplete penetrance of variants that are incompletely identified[1][5]. Recent proteomic analysis has revealed a remarkable and previously underappreciated role for immune dysregulation in hEDS pathophysiology, with mass spectrometry-based proteomic analysis of serum from hEDS patients identifying 35 differentially expressed proteins, 43 percent of which are involved in the complement cascade and 80 percent of which participate in immune, coagulation, or inflammatory pathways[9][12]. These findings challenge the traditional paradigm of hEDS as purely a primary connective tissue disorder, instead supporting a revised understanding that includes significant innate immune dysfunction as a core pathophysiological feature[9][12].

The complement system dysfunction identified in hEDS is particularly striking, with significant reductions in classical pathway components including C1QA, as well as terminal complement components C8A, C8B, and C9, and central complement component C3, all showing consistent and reproducible reductions across hEDS patients independent of age, sex, or autoimmune status[9][12]. These reductions in complement components are notable because C8 and C9 are critical for assembly of the membrane attack complex (MAC), the terminal effector of complement activation responsible for direct killing of pathogenic microorganisms and removal of damaged cells, suggesting that impaired MAC formation could compromise pathogen clearance and inflammatory regulation[9][12]. Indeed, increased infection rates have been reported in hEDS patients, a finding consistent with complement deficiency and impaired innate immune function[9][12]. Beyond complement dysregulation, hEDS serum demonstrates significant alterations in circulating cytokine profiles reflecting broader immune dysregulation. Cytokine profiling reveals altered levels of multiple key immune mediators including downregulation of myeloperoxidase (MPO), a neutrophil enzyme involved in reactive oxygen species production and microbicidal activity, and Pentraxin 3 (PTX3), an innate immune recognition protein produced by activated neutrophils, suggesting alterations in neutrophil-driven immune responses and tissue remodeling[9][12]. The reduction in tissue growth factors including hepatocyte growth factor (HGF) and transforming growth factor-α (TGF-α), combined with dysregulation of profibrotic mediators including IGFBP-2 elevation, creates an immunological microenvironment characterized by impaired tissue repair signaling and altered inflammatory responses[9][12].

The cellular and molecular mechanisms underlying ECM dysregulation in hEDS overlap substantially with those identified in cEDS and vEDS despite the absence of identified collagen mutations, with hEDS fibroblasts displaying characteristic disorganization of multiple ECM components and abnormal integrin receptor organization[2][5][38][39]. Gene expression profiling of hEDS fibroblasts reveals dysregulation of genes encoding cell-matrix interaction proteins, inflammatory and pain response mediators, and evidence of fibroblast-to-myofibroblast transition with acquisition of myofibroblast markers including α-SMA and altered cadherin-11 organization[2][5][38][39]. Emerging findings from microRNA (miRNA) profiling of hEDS fibroblasts provide novel insights into disease etiopathogenesis, with differential expression of multiple miRNAs that target ECM-related genes, suggesting that epigenetic mechanisms involving post-transcriptional gene regulation through miRNA-mediated silencing contribute to the complex molecular pathology of hEDS[2][5][39]. Notably, hEDS cells show dysregulation of miRNAs including hsa-miR-378a-3p, hsa-miR-224-5p, and hsa-let-7f-5p that target numerous ECM-related genes and transcription factors, indicating that altered miRNA expression contributes to the characteristic ECM disarray and gene expression perturbations observed in hEDS[39].

Autonomic Nervous System Dysfunction and Dysautonomia

Beyond the well-recognized connective tissue pathology, EDS pathophysiology encompasses dysautonomia, a disorder of the autonomic nervous system that affects a substantial proportion of EDS patients, particularly those with hEDS[26][29]. Dysautonomia, encompassing autonomic dysfunction affecting the sympathetic and parasympathetic nervous systems that regulate involuntary bodily processes including heart rate, blood pressure, sweating, digestion, and bladder function, represents a multi-system manifestation of EDS that significantly impacts quality of life and clinical complications[26][29]. Recent comprehensive evaluation of 270 hEDS patients revealed that widespread but mild autonomic failure is present in 90 percent of hEDS patients on formal autonomic testing, with highly prevalent complaints including orthostatic sudomotor symptoms (>90% prevalence), vasomotor symptoms, gastrointestinal dysmotility, and pain in a similar proportion[26]. The mechanisms underlying autonomic dysfunction in EDS remain incompletely understood but likely involve both structural abnormalities of autonomic nerve fibers and dysregulation of autonomic signaling, with evidence suggesting roles for small fiber neuropathy, altered sympathetic outflow, and impaired cerebrovascular regulation[26][29].

Orthostatic intolerance, affecting the majority of hEDS patients, manifests as symptoms triggered by standing including lightheadedness, palpitations, tremor, weakness, blurred vision, exercise intolerance, and fatigue that reflect inadequate cardiovascular and cerebrovascular compensation for positional changes[26][29]. The pathophysiology underlying orthostatic intolerance in hEDS appears multifactorial, with approximately 33 percent of hEDS patients meeting diagnostic criteria for postural tachycardia syndrome (POTS), characterized by an excessive increase in heart rate of 30 or more beats per minute upon standing or head-up tilt in the absence of orthostatic hypotension[26][29]. Additional mechanisms of orthostatic intolerance include impaired cerebral blood flow regulation, with 79 percent of hEDS patients demonstrating reduced orthostatic cerebral blood flow velocity that correlates with orthostatic dizziness symptoms, suggesting that cerebral hypoperfusion contributes significantly to orthostatic intolerance in this population[26]. Small fiber neuropathy, detected in 82 percent of hEDS patients using combined structural and functional diagnostic criteria, represents another significant neurological manifestation that may contribute to both pain pathophysiology and autonomic dysfunction[26]. The small unmyelinated C-fiber and thinly myelinated A-delta nerve fibers that comprise the small fiber neuropathy detected in EDS patients are thought to mediate both nociceptive pain signaling and autonomic regulation of blood vessels and other target organs, suggesting that the same neural pathology contributes to both pain and autonomic symptoms[26].

Central Sensitization and Chronic Pain Pathophysiology

Chronic widespread pain represents one of the most common and disabling manifestations of EDS, particularly in hEDS where pain often becomes the primary driver of disability and psychological distress. The pain in EDS results from complex interactions between peripheral nociceptive input, small fiber neuropathy, and dysregulation of central pain processing mechanisms including central sensitization[26][27][30]. Central sensitization, defined as an increase in the excitability of neurons within the central nervous system such that normal inputs begin to produce abnormal pain responses, represents a critical pathophysiological mechanism wherein pain itself becomes altered and amplified independent of ongoing peripheral tissue damage[27][30]. In the dorsal horn of the spinal cord and brainstem pain processing regions, repeated or intense nociceptive input triggers maladaptive neuroplastic changes characterized by enhanced synaptic transmission, reduced inhibitory neurotransmission, and altered gene expression patterns that collectively amplify pain signaling[27][30]. The molecular basis of central sensitization involves dysregulation of multiple neurotransmitter systems including excessive glutamate signaling through N-methyl-D-aspartate (NMDA) receptors, enhanced expression of AMPA receptors on postsynaptic neuronal membranes, and reduced GABAergic and glycinergic inhibitory neurotransmission[27][30]. Additionally, substance P, a neuropeptide co-released with glutamate from C-fiber nociceptors, activates neurokinin receptors on dorsal horn neurons and amplifies NMDA receptor-mediated pain signal amplification[27][30].

The peripheral nociceptive input that drives central sensitization in EDS originates from both small fiber neuropathy affecting unmyelinated C-fibers and thinly myelinated A-delta fibers, as well as from ongoing tissue damage and inflammatory processes in joints and connective tissues[26][27][30]. Small fiber neuropathy in EDS results from structural abnormalities of nerve fiber innervation patterns within the dermis, documented through skin biopsy showing reduced intraepidermal nerve fiber density and abnormal distribution patterns[26]. The inflammatory environment in EDS tissues, characterized by dysregulated cytokine production including elevated pro-inflammatory mediators, likely contributes to both peripheral nociceptor sensitization and central amplification of pain signals[27][29]. Inflammatory mediators including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) act on peripheral nociceptors to lower pain thresholds, a process termed peripheral sensitization, while simultaneously driving central neuroinflammation through microglial activation and release of additional pro-inflammatory cytokines[27]. The dorsal horn microglia, resident macrophages that normally maintain basal surveillance functions, become activated in response to persistent nociceptive input or systemic inflammation and release pro-inflammatory mediators that enhance neuronal excitability and amplify pain processing[27]. This neuroinflammatory amplification of pain represents a feed-forward mechanism wherein inflammatory signals activate microglia, which release additional inflammatory mediators that enhance pain signal processing, thereby amplifying the pain experience beyond what the peripheral nociceptive input alone would generate[27].

Psychological and emotional factors significantly modulate central sensitization in EDS, with stress, anxiety, and traumatic life experiences capable of priming the pain system through distinct mechanisms involving altered catecholamine metabolism and enhanced nociceptor responsiveness[27][30]. Patients with central pain processing disorders including EDS often demonstrate hyperalgesic priming, wherein prior painful or stressful events result in enhanced and prolonged pain responses to subsequent stimuli through activation of distinct kinase and gene transcription pathways within nociceptors[27]. This

Ehlers-Danlos Syndrome

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Environmental Factors

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)

Comprehensive Pathophysiology of Ehlers-Danlos Syndrome: Molecular Mechanisms, Cellular Dysfunction, and Multi-System Complications

Fundamental Genetic Architecture and Classification of Ehlers-Danlos Syndrome

Core Pathophysiological Mechanisms: Collagen Synthesis, Processing, and Extracellular Matrix Organization

Endoplasmic Reticulum Stress and Protein Quality Control Mechanisms

Autophagy Dysregulation and Intracellular Protein Accumulation

Integrin Signaling and Cell-Matrix Interactions in Classical and Hypermobile EDS

Type-Specific Pathophysiology: Classical Ehlers-Danlos Syndrome

Type-Specific Pathophysiology: Vascular Ehlers-Danlos Syndrome

Type-Specific Pathophysiology: Hypermobile Ehlers-Danlos Syndrome and Immune Dysregulation

Autonomic Nervous System Dysfunction and Dysautonomia

Central Sensitization and Chronic Pain Pathophysiology